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SOME DIAGNOSTIC AND THERAPEUTIC 
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STELLINGEN Bij het proefschrift Some diagnostic and therapeutic controversies in glaucoma addressed 1. Gebruik van topicale beta-blokkers verkort het leven niet (dit proefschrift). 2. Een afwijkende corneacompensatie is geen belangrijke reden van fout­negatieve misclassificatie door de GDx (dit proefschrift). 3. Ingewikkelde oplossingen voor perimetrische problemen zijn meestal niet beter clan simpele oplossingen (dit proefschrift). 4. Ingewikkelde oplossingen voor financieringsproblemen in de gezondheids­zorg lijken geprefereerd te worden boven simpele oplossingen (de dagelijkse praktijk). 5. Het ontbreken van voorkeurslocaties voor glaucomateuze uitval vergroot de praktische inzetbaarheid van de frequency doubling perimeter (dit proefschrift). 6. Calciumantagonisten moeten niet als therapeuticum in het arsenaal van de glaucoomspecialist opgenomen worden (dit proefschrift). 7. Vasculaire factoren, als ze al een rol spelen in de pathogenese van glaucoom, zijn complexer clan vaak gedacht wordt (dit proefschrift). 8. Succes = Resultaat- Verwachting (P.T. Khaw). 9. Incidentele problemen behoeven slechts zelden een structurele oplossing. 10. Waar het internet bij oordeelkundig gebruik een van de belangrijkste bronnen van medische informatie is, is het in alle andere gevallen een van de belangrijkste bronnen van medische disinformatie. 11. Essentially, all models are wrong, but some are useful (G.E.P. Box). 12. Het woord zorgverzekeraar blijkt in de praktijk vaak een contradicti in terminis te zijn. 
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History of glaucoma Since it was first used in the Hippocratic Aphorisms, the definition of the term glaucoma has changed several times over the course of the centuries that followed.1 In ancient Greek the word glaucoma supposedly meant the dull sheen or glaze of blind­ness and was used in the Hippocratic Aphorisms to describe the blindness that comes on in advancing years that was associated with a glazed appearance of the pupil. As this glazed appearance of an eye may be the consequence of either advanced cataract or corneal clouding due to raised intraocular pressure, it is clear that the Hippocratic Aphorisms make no clear distinction between cataract and glaucoma. In fact, the term glaucoma was prob­ably used without any pathological connotation but simply to describe blindness due to various causes, among which modern day glaucoma. Only at a later date was it recognized by Celsus and other early Christian writers that condi­tions behind the pupil which gave rise to blindness could be differentiated into two groups: cataracts that were amenable to operative treatment and glaucomas that were not.1 In the tenth-century Book of Hippocratic Treatment by the Arabian writer At-Tabari, 1 the first recognition of a disease associated with a rise in intraocular pressure, and thus cor­responding to what is now known as glaucoma, was described. In this book an increased tenseness of the eye was always concurrent with inflammation. This notion would persist for nearly nine centuries. In European literature, it was Richard Bannister, an English oculist and author of the first book of ophthalmology in English, 2 who in 1622 made the first original and clear recogni­tion of glaucoma, then called gutta serena, as a disease with a tetrad of features: increased intraocular pressure, long duration of the disease, the absence of the perception of light and the presence of a fixed pupil. The first accurate description of glaucoma with raised intraocular pressure was not given until the beginning of the nineteenth century. In 1818 a publication by Demours estab­lished a rise in intraocular pressure as a central concept. 3 In 1823 in London, Guthrie named glaucoma as a disease characterized by hardness of the eye.4 Finally, the essential feature of increased intraocular pressure was fully established by McKenzie, a Scottish cli­nician who, in the second edition of his widely read textbook from 1835,5 ascribed the raised tension in both chronic and acute glaucoma. The final clinical observation in this epoch was Donders's (1862) unifying concept, 1 where he described an increased intraocular pressure occurring without any inflammatory symptoms as Simple Glaucoma. General Introduction 9 
Hereafter, glaucoma was defined by most textbooks according to the traditional triad of increased intraocular pressure, typical cupping without pallor of the optic disk and charac­teristic visual field loss. The concept of glaucoma has been further refined, especially over the last four decades. In 1973, for the first time, Drance provided a definition of glaucoma as a disease of the optic nerve (an optic neuropathy) caused by numerous factors, called risk factors.6 Modern definition of glaucoma Currently glaucoma is defined by the European Glaucoma Society as chronic, progressive optic neuropathies that have in common characteristic morphological changes at the optic nerve head and retinal nerve fiber layer in the absence of other ocular disease or congenital anomalies.7 Progressive retinal ganglion cell death and visual field loss are associated with these changes. Increased intraocular pressure has been removed from the definition of glaucoma and is currently regarded instead as the most important risk factor for glaucoma. The reason for this is that glaucomatous damage can occur with normal intraocular pressure, so-called normal tension glaucoma, and that intraocular pressure can be increased without any signs of damage to the optic disk or visual field, so-called ocular hypertension.7•8 In the literature, over sixty types of glaucoma have been described, all differing in clinical presentation, pathophysiology and therapeutic approach. 8 Clinically the most important distinction between different types of glaucoma is the clas­sification of open-angle or closed-angle glaucoma, which is based on the anatomy of the anterior chamber angle as viewed by gonioscopy. A further division into primary and sec­ondary glaucoma can also be made. Primary glaucomas have no known association with any ocular or systemic disorder causing increased resistance to aqueous outflow. Secondary glaucomas have an identifiable ocular or systemic disorder that is responsible for decreased aqueous outflow. Other schemes for classifying glaucoma, based on age of onset of the glau­coma, the initial height of intraocular pressure and mechanism of outflow obstruction, have gained some popularity in recent years; however, the division into open- or closed-angle and primary or secondary glaucoma remains the most widely used. In the Western world the most common form of glaucoma is primary open-angle glau­coma (POAG).7-9 This type of glaucoma is characterized by an open chamber angle upon gonioscopy and the absence of ocular or systemic abnormalities that explain the increase 10 Chapter 1 
in intraocular pressure. By far most patients in the studies contained in this thesis were diagnosed with POAG. The pathophysiology of open-angle glaucoma Even with the current state of science, the many theories that have been and are still being advanced regarding the etiology of glaucoma indicate the elusiveness of the problem and the dissatisfaction with previous explanations. For this reason one can only concur with the observation of Duke-Elder in 1929,1° who concluded that "the whole question is in need of thorough investigation from its very foundation." However, as the pathophysiology of disease holds important information with regard to its understanding, treatment and detec­tion, in the following sections some of the theories on the pathophysiology of glaucoma will be addressed. Before postulating a hypothetical mechanism for the pathophysiology of glaucoma, it would be sensible to determine the most likely locus of glaucomatous injury. This is best done by studying the clinical changes reflecting the anatomical nature of progression.II In the case of glaucoma, there are several locations on the visual pathway where a spread of death of the retinal ganglion cells or their axons could occur: - spread among adjacent retinal ganglion cells in the eye - spread among adjacent axons in the optic nerve, chiasm or tract or lateral geniculate nucleus - spread among adjacent axons at the disk. It is possible to predict the resultant visual field defect changes that would take place if spread where to occur in each of these locations. If spread would occur among adjacent ganglion cells in the retina, the resulting visual field loss would be a centrifugally spreading visual field defect. For instance, a nasal step might spread out in all directions from its center and would cross the horizontal meridian. This is not the experience of clinicians and was not noted in a study by Boden who investigated the development of glaucomatous visual field defects. I2 In this study among 96 patients, only twelve early glaucoma patients showed defects crossing over the horizontal meridian. Eleven of these patients had non-contiguous defects suggesting a second area of injury rather than spread. Only one patient had possible spread over the horizontal meridian, suggesting that crossing the horizontal meridian is a rarity in glaucoma, which contradicts what might be expected if the site of injury was the retinal ganglion cell in the eye. General Introduction 11 
Spread among adjacent axons in the optic chiasm or tract or lateral geniculate nucleus is also unlikely because these sites would also not result in visual field defects that respect the horizontal meridian. The visual field defects in these types of injury would be far more likely to respect the vertical meridian. 1 1 ·13 Spread among axons in the optic nerve behind the disk is also unlikely because there is rearrangement of axons from the supero- and infero­temporal poles within a few millimeters after entering the optic nerve. This would result in a spread of visual field defects that do not respect the horizontal meridian such as the spread of a defect cause by anterior ischemic optic neuropathy.1 1 ·14 Therefore, the most likely locus of injury in glaucoma is the disk itself. This is supported by the morphologic changes in glaucoma, the cupping and splinter hemorrhages that occur at the disk. Furthermore, no retinal changes are seen in glaucoma except as a result of axonal death. After determining that glaucoma is probably the result of an injury to the optic disk, a second question that needs to be answered is how to explain the progression at the disk. This can occur either as the result of axon-to-axon progression (i.e., one dying axon causes the axon next to it to die as well) or because of changes to the microenvironment. Axon­to-axon progression is improbable as it does not occur in other diseases of the visual path­ways.1 1 ·15 For instance, when the optic tract is severed unilaterally (for example, as part of a neurosurgical procedure to remove a tumor), this results in contralateral hemianopia and retrograde axonal degeneration in the ipsilateral temporal retina and contralateral nasal retina. Some of the axons of the nasal ganglion cells of the ipsilateral (and temporal gan­glion cells of the contralateral) optic nerve are immediately adjacent to these dying axons. If axon-to-axon progression was an important mechanism, one would see a gradual enlarge­ment of the hemianopia across the vertical meridian. This suggests that it is unlikely that axon-to-axon progression is significant in visual pathway disease and probably in glaucoma as well. It is, therefore, much more likely that a change in the microenvironment of the site of injury is responsible for the damage found in glaucoma. Currently there are three main hypotheses concerning change in the microenvironment of the optic disk and, therefore, the development of glaucoma: the vascular theory, the mechanical theory and a combina­tion of both of these theories. The vascular theory The vascular theory of glaucoma is based on the assumption that ischemic injury to the optic nerve causes the death of axons of the optic nerve independent of an increase in intraocular pressure. 16 One of the main arguments in favor of this theory is the fact that a large proportion of glaucoma patients do not have increased intraocular pressure. Over 12 Chapter 1 
147 years ago, Von Graefe was the first to describe glaucoma without high intraocular pressure, 17•18 which he called amaurosis with excavation. From both clinical- and popu­lation-based studies we know that a large proportion of glaucoma patients do not have supranormal intraocular pressure.19 -21 On the other end of the spectrum lie the results of the ocular hypertension treatment study where only ten percent of participants with supranormal intraocular pressure developed glaucoma. 22 For these reasons intraocular pres­sure cannot be the only inciting event in glaucoma. Other arguments linking ischemia to glaucoma stem from many different studies that demonstrate altered blood flow parameters in the eyes of glaucoma patients. 16 The earliest of these studies was carried out in the 1940s when excisions of early stage glaucomatous eyes revealed signs of circulatory stasis linking ischemia to the early stage of glaucoma. 23•24 Later on, many studies using first fluorescein angiography, and later techniques such as color Doppler imaging and confocal scanning laser ophthalmoscopy, measured differences in blood flow parameters between healthy eyes and glaucomatous eyes. 16•25 However, one problem with virtually all these described methods of blood-flow measurement is that repeatability of these measurements is low. In addition, other arguments often used to advocate the vascular theory, such as important associations between systemic hypertension or atherosclerosis and glaucoma, have lost some weight with the recent publication of incident data from population-based studies where such associations could not be demonstrated. 26 Therefore, at this time there is not enough evidence to completely accept a reduction of optic nerve blood flow as the main cause of glaucoma, although it may have some effect. The mechanical theory The mechanical theory of the development of glaucoma proposes that a direct mechanical effect caused by intraocular pressure results in the death of the optic nerve fibers. In this theory, an increase in intraocular pressure causes the nerve fibers of the optic nerve to be compressed against the lamina cribrosa at the optic disk.11 This compression of optic nerve fibers can cause the nerve fibers to stretch. However, studies by Smith and colleagues with axons from cultured human neuron-like cells have shown that axons are relatively imper­vious to damage from stretching as long as this occurs at a slow rate of displacement. 27 This would entail that shearing forces caused by stretching are not the main mechanism by which optic nerve fibers are damaged or that fluctuation of intraocular pressure is more important than the absolute level of such pressure. However, apart from shearing forces stretching axons, intraocular pressure can result in axonal death in other ways. Axoplasma flow can be interrupted as shown by Maxwell, 28 which in turn can cause diminished pro­tein transportation and result in the death of the axons. The main argument behind the mechanical theory is the close relationship between intraocular pressure and glaucoma. A myriad of studies of different design all demonstrate an association between intraocular General Introduction 13 
pressure and glaucoma.29-34 Furthermore, reducing intraocular pressure reduces progression of glaucomatous damage. Another argument supporting this theory is that it explains, at least in part, those observations that can be made in patients with glaucoma. Disk hemor­rhages that occur in glaucomatous eyes before progression, often with neuroretinal rim loss at the site of the hemorrhage, can be explained as hemorrhages that occur at the site of maximum stretch.11 However, as mentioned earlier, a large percentage of glaucoma patients do not have supranormal intraocular pressure, though perhaps supranormal should not be defined using population-based standards but should be determined individually. It is likely that the mechanical theory does explain glaucoma in part, but to develop glaucoma other conditions need to be present that make the eye more susceptible to intraocular pressure. Combined vascular and mechanical theory In the combined theory of glaucoma, neither the vascular nor the mechanical theory is considered sufficient to explain the entire pathophysiology of glaucoma alone. According to this theory both vascular and mechanical factors contribute to the disease process. Rather than direct mechanical damage to axons resulting from increased intraocular pressure as the cause, the combined theory states that increased intraocular pressure causes capillaries in the optic nerve to close, which results in diminished blood flow to the axons of the optic nerve, which in turn is what causes the axons to die. The central factor in the combined theory is perfusion pressure on the optic nerve. Perfusion pressure is defined as the mean arterial blood pressure in the optic nerve vessels minus the intraocular pressure.16 The lower the perfusion pressure the more damage occurs to the optic nerve. The advantage of this combination theory is that it explains both the large effect that intraocular pressure has (higher intraocular pressure for constant blood pressure would result in lower perfusion pressure and thus in more damage) as well as how glaucoma develops in eyes with normal pressure (lower blood pressure for constant intraocular pressure would also result in lower perfusion pressure and thus in more damage). However although perfusion pressure has theoretical advantages over for instance intraocular pressure, in most studies the association between perfusion pressure and glaucoma is rather weak, at least weaker than the associa­tion between intraocular pressure and glaucoma. This may be due to inter-individual dif­ferences in susceptibility to perfusion pressure, which may in turn be caused by differences in autoregulation mechanisms.16 For this reason also the combined theory does not explain the origin of glaucoma fully. 14 Chapter 1 
Epidemiology of glaucoma Primary open-angle glaucoma is the most common form of glaucoma in the Western world.9 The frequency of occurrence of a disease is best described by its prevalence and incidence. The prevalence of a disease is the number of instances of a given disease in a given popula­tion at a designated time. The incidence of a disease is the number of newly diagnosed cases of a disease over a specific time period. However, citing a general prevalence or incidence number for glaucoma is almost meaningless, because race and age have such a profound effect that prevalence and incidence rates are best described in relation to those variables. In the Netherlands, with a mainly Caucasian population, the prevalence of primary open­angle glaucoma in individuals 55 years of age and older is 0.8%.35 The five-year incidence risk of primary open-angle glaucoma in this same population is 1.2%.36 These rates are comparable to prevalence and incidence rates as measured in other studies in the Western world. The Baltimore Eye Study found a prevalence of 1.1 % and the Barbados Eye Study recorded a prevalence of 0.8% in Caucasians over age 40.37•38 Incidence rates are also quite similar; for instance, the Dalby study found an incidence rate of 0.24% per year.39 The Visual Impairment Project showed an incidence rate of 1.1%,40 which is somewhat lower; however, after correcting for age, the results were similar. The burden of glaucoma Worldwide it is projected that an estimated 60.5 million people will be affected by glau­coma by 2010, and this number is expected to increase to 79.6 million people by 2020.9 The number of people who are bilaterally blind as a consequence of glaucoma is estimated to be 8.4 million (4.5 million due to POAG) by 2010, rising to 11.2 million (5.3 million due to POAG) people by 2020.9 This makes glaucoma, after cataract, the second leading cause of blindness in the world and, since cataract is amenable to therapy, glaucoma is the leading cause of irreversible blindness in the world today. Risk factors for glaucoma As mentioned earlier, overall prevalence and incidence rates are not a very useful measure­ment because of the influence that risk factors have on the development of glaucoma. The term "risk factor" describes features that increase the chance of developing a disease and may be causal to the disease.41 Risk factors may be identified because they are statistically associated with the disease and could conceivably have played an essential role in the inci­dence of the disease. Currently the most consistently identified risk factors for primary open-angle glaucoma are intraocular pressure, age, race, family history, myopia and central corneal thickness.41•42 General Introduction 15 
lntraocular pressure Nearly every study, both clinic-based and population-based, has shown that the level of intraocular pressure is a risk factor for POAG incidence, prevalence and progression. 29-35 Currently it has not been determined which aspect of intraocular pressure is the most important: the average IOP, the maximum IOP or the range of fluctuation of IOP.41 For many years intraocular pressure was part of the definition of glaucoma. However, glaucoma can develop in persons with consistently normal intraocular pressure. This was noted as early as 1932 by Magitot and has been confirmed in the results of recent population-based studies where some twenty-five percent of participants with POAG have an intraocular pressure in the normal range. For this reason, intraocular pressure is no longer part of the definition of glaucoma, though it does remain one of the most important risk factors for glaucoma. This is underscored by the fact that every randomized clinical trial in the field of glaucoma has shown that reducing intraocular pressure slows down visual field loss and that, furthermore, lowering intraocular pressure is the only proven therapy for glaucoma at this time. Age Advanced age is consistently associated with an increased risk of primary open-angle glau­coma. For example, in the Netherlands the five-year incidence rate rose from one percent in individuals over age 60 to three percent in individuals over 80.36 In assessing this factor, we could think of age as a surrogate that stands for the deterioration of relevant tissues with time, potentiating ganglion cell death. Older age is also a measure of the length of time that the person is exposed to other risk factors before developing disease. In this sense, it is not inherently a cause, but actually a measure of the amount of other factors. Age may also be a measure of how long the person with POAG has had the disease; thus, age stands for duration and may be expected to be associated with greater damage when the disease is progressive. Race One problem with race as a risk factor is that definitions of ethnic derivation are often poorly specified. Caucasians consist of a diverse group, as do, for instance, the populations of India and China.43 However, these determinations are the closest thing to a specification of an individual's background. In this light, it has been consistently found that persons who are African derived (black) are more likely to develop POAG, to develop it at an earlier point in their lives and to develop it to a more severe degree than all other ethnici­ties. In the Barbados Eye study, a four year incidence rate of 2.2% was found in blacks,44 which is significantly higher than the 1.2% five-year incidence rate in the Netherlands.36 16 Chapter 1 
Reasons for this difference may be that black persons on average have larger optic disks with smaller rims, which may make them more susceptible to glaucomatous damage, and there is also some evidence that black persons may have thinner corneas. Studies from southern India suggest that persons there may have higher rates of POAG than European-derived persons.41 Chinese seem to have similar rates of POAG as Europeans.45 Two studies of Hispanic-Americans suggested more POAG than in Europeans, although the two studies differed from each other in disease definition,41 probably explaining a substantial difference in age-specific prevalence between the studies. Family history of glaucoma Having a family history of affected close relatives is a risk factor for POAG, although not a simple one to investigate. In parallel to ethnicity, which is important, having an affected family member is also perhaps an even stronger expression of genetic susceptibility. Yet, it could be that some families are simply more prone to being examined for it. Hence, these families may be no more likely to have POAG, but are just more likely to report that a family member is affected. However, all the available family members of glaucoma patients in the Rotterdam study underwent examinations.46 This approach reduced any ascertain­ment bias due to self-reporting. The results of this study showed that a first-degree relative of a glaucoma patient ran a ten times higher risk for developing glaucoma. This increased risk is independent of other risk factors such as intraocular pressure. The Barbados popula­tion family study revealed that ten percent of living relatives had glaucoma.47 Central corneal thickness Central corneal thickness was introduced as a risk factor for glaucoma, based on the results of the ocular hypertension treatment study that showed that persons with a thinner cornea were more likely to develop glaucoma. 48 Of course, thinner corneas produce lower applana­tion IOP readings. Hence, persons with thin corneas would be missed using IOP screening only and so are more likely to develop optic nerve damage before it can be detected. Still, a small central corneal thickness remains a risk factor for glaucoma even when corrected for its effect on intraocular pressure, which means that corneal thickness is probably a sur­rogate for other, as yet undetermined, parameters that more directly impact POAG risk. Myopia Myopia has been associated with POAG in many studies. This could be the result of more frequent contact between eye-care providers and patients with myopia as compared 
to emmetropes resulting in ascertainment bias. However, in a population-based study 
General Introduction 17 
among Australians, there was a two-fold increase in risk for patients with mild myopia and a three-fold increase in risk for patients with higher myopia, and this effect was present after adjusting for IOP level.49 Furthermore, patients with myopia did not have signifi­cantly higher IOP than did others with POAG. Hence, the effect of myopia may be the response to IOP levels that are tolerated by others. In addition, the Beaver Dam Eye Study found a 1.6-fold increase in risk for patients with myopia and a study from Japan found a 1.9-fold increase in risk for those with mild myopia that rose to 2.6 for moderate to severe myopia.4o,so Controversial risk factors A great number of other possible risk factors have been linked to glaucoma in the past. Several factors such as an increased cup-to-disk ratio, decreased choroidal thickness, optic disk crescent and optic disk hemorrhage do not seem to be actual risk factors in the sense that their presence increases the chance of developing glaucoma; instead, these are more likely to reflect changes that have already occurred in a glaucomatous eye.41 ·5 1 There is an ongoing debate over other possible risk factors for glaucoma. And this is especially true for two systemic risk factors that were traditionally associated with glaucoma: diabetes and hypertension. Diabetes was assumed to be a risk factor for glaucoma, based on clinical studies and several population-based prevalence studies (The Rotterdam Study showed a 3.1-fold increased risk, the Blue Mountain Eye Study showed a 2.1-fold increased risk).5253 However, ten years ago diabetes failed to show any association with glaucoma in a randomized clinical trial, and population-based incidence studies (for instance, the Rotterdam Study) did not show any association as well.54·55 So, the earlier assumption was most probably due to ascertain­ment bias in clinical studies: a diabetic patient is more likely to have an eye exam and, therefore, more likely to be detected as a glaucoma patient. However, ascertainment bias does not explain the results of the earlier population-based prevalence studies. Therefore, it may be that diabetes is a risk factor for glaucoma, which fails to show up in modern incidence studies because diabetic patients are screened by ophthalmologists for diabetic retinopathy and, as a result of the old dogma that diabetics are prone to develop glaucoma, are more likely to be treated preventatively for glaucoma. Systemic hypertension as a risk factor for glaucoma has been a matter of dispute since the late nineteenth century. The reason for this dispute arising was a presumed causal relationship between raised blood pressure and raised intraocular pressure. In 1898 Terson and Campos described no causal relationship between these two entities; however, their immediate fol­lowers, among others Joseph in 1904, and Frenkel and Garipuy in 1906, had a different 18 Chapter 1 
opinion. 1 In 1914, Smith presented evidence showing that arteriosclerosis and high general blood pressure might be of etiologic importance in glaucoma. Ever since this first descrip­tion of the association between systemic hypertension and glaucoma, many observations from clinically based studies have followed. However, as with diabetes, these studies are plagued by ascertainment bias, that is, a patient with systemic hypertension and arthroscle­rosis is more likely to visit an ophthalmologist and is thus more likely to be diagnosed with glaucoma. During this period, various studies appeared in the literature, stemming from a publication by Drance in 1972,56 implicating not high, but low blood pressure as a causative factor in glaucoma. Even population-based prevalence studies have not been able to clarify this issue. The Blue Mountains Eye Study recorded a 1.6-fold increased risk of glaucoma in participants with systemic hypertension. And the Egna-Neumarkt study also showed a small 1 .4-fold risk increase.57·58 However, the confidence interval in this latter study showed that this increase was not significant. While the Baltimore Eye Survey, on the other hand, detected that hypertension did not increase the risk of POAG in a population.59 It actually described a far more complex relationship between systemic hypertension and glaucoma. In young persons with systemic hypertension POAG occurred less frequently, while older persons with systemic hypertension were more likely to have POAG. These findings would suggest that age is a surrogate for duration of hypertension and that some aspects of hyper­tensive effects on vessels or their function over years of exposure may predispose to POAG. Perhaps young persons with systemic hypertension benefitted from an increased perfusion pressure due to their high blood pressure, while in older persons this advantage was negated due to atherosclerosis. However, this latter assumption has been disputed by a finding of the Rotterdam Study that showed no association between atherosclerosis and glaucoma. Other data from Rotterdam have also shown a complex relationship between blood pressure and glaucoma. A recently published study from Hulsman found that POAG with increased intraocular pressure was associated with low diastolic perfusion pressure, 60 whereas low diastolic perfusion pressure decreased the risk of normal tension glaucoma. Clinical evaluation of glaucoma The diversity found in clinical appearances often makes the diagnosis of glaucoma dif­ficult. This diagnostic problem is increased by the fact that early glaucomatous field loss often goes unnoticed. Unfortunately, once it does occur, glaucomatous visual field loss is irreversible.7•8 For the appropriate management of glaucoma, the accurate determination of the specific type of glaucoma, the severity of the condition and possible progression are important. Of course a history and complete opthalmological exam, including slit lamp biomicros­copy, measurement of intraocular pressure, gonioscopy and ophthalmoscopy need to be General Introduction 19 
performed to determine the type of glaucoma. For the determination of severity and the detection of progression, inspection of the optic nerve and visual field examination are especially important. Inspection of the optic nerve The most common way to inspect the optic nerve is using slit lamp biomicroscopy. This exam allows for determination of the ratio between the optic disk cup and the neuroretinal rim, the color of the neuroretinal rim, the size of the optic disk and the presence of peripap­illary atrophy. A normal optic disk has a neuroretinal rim with a pink color, a relatively uni­form width and a cup-disk ratio smaller than 0.7. Other signs of abnormality that can be observed by slit lamp biomicroscopy are splinter hemorrhages and nerve fiber layer defects. Two problems arise when trying to inspect the optic disk using slit lamp biomicroscopy alone. First, because there is a large inter-individual variation in optic disk appearance, diagnosis of glaucoma is sometimes difficult. Second because of large interobserver vari­ability and difficulty in quantifying slit lamp biomicroscopy findings, long-term follow­up based only on slit lamp biomicroscopy, especially in clinics where patients are seen by multiple doctors, is difficult. An attempt has been made to improve patient follow-up by using stereoscopic photography of the optic nerve, but this has had disappointing results and has brought about no improvement in progression detection when compared to slit lamp biomicroscopy. 61 Although in current clinical practice slit lamp biomicroscopy remains a cornerstone of glau­coma diagnosis because of its ease of use, low cost and ubiquitous availability, several instru­ments have been developed during the last decade to aid in the inspection of the optic nerve. The three most widely used instruments are the Heidelberg Retina Tomograph (HRT), Ocular Coherence Tomography (OCT) and the GDx Nerve Fiber Analyzer (GDx).61 The Heidelberg Retina Tomograph (HRT) The HRT is a confocal laser-scanning ophthalmoscope system designed to acquire and analyze three-dimensional images of the posterior segment of the eye. 61 In the HRT system a focused laser beam scans the fundus and the amount of light reflected at each point is measured. The instrument makes sequential optical sections of 15 x 15 degrees (with a reso­lution of 384 x 384 pixels) of an image field on the retina at depth intervals of 1/16 mm. At each location in the image stack, the light intensity varies through the depth of the scan series. It is assumed that this intensity variation is largest at the tissue surface. Thus, this instrument allows one to make an exact topographical map of the surface of the optic disk. By applying a specifically designed algorithm to this topographical map, the instrument is 20 Chapter 1 
able to calculate the optic disk cup-and-rim volume and area. One major advantage of the HRT system is that each new version is designed to be compatible with former versions. This makes long-term follow-up of glaucoma patients possible and it is even possible to ana­lyze data, gathered using early versions, with the more modern diagnostic algorithms found in the new versions. One drawback of this system, however, is that the algorithm used to calculate optic disk parameters relies on an exact determination of the border of the optic nerve, which can be difficult. Ocular Coherence Tomography (OCT) OCT imaging is analogous to ultrasound B-mode imaging, except that it uses light instead of sound.61•62 Its significant benefit is that using light rather than sound provides signifi­cantly higher spatial resolution; axial resolutions of up to 10 µm are possible. This is made possible by using a low-coherence light source and interferometry to generate an optical section through retinal tissues. When a beam of light is directed into the eye, it is reflected back from boundaries between different tissues and backscattered differently from tissues that have different optical properties. This enables the OCT to make an optical section through the retina, showing the different retinal layers. One theoretical advantage of the OCT is that, where the HRT is only able to examine optic disk parameters and the GDx (see the next section) is only able to detect the retinal nerve fiber layer around the optic disk, the OCT is able to scan both the optic disk and the retinal nerve fiber layer. In addition, the OCT is equipped with software that is able to automati­cally identify the nerve fiber layer through the detection of different intensity thresholds. However, one drawback of this system is that it is currently under heavy development, which makes the current version not suitable for long-term follow-up. The GDx Nerve Fiber Analyzer The Gdx Nerve Fiber Analyzer (Gdx) is a technique that makes the assessment in vivo of the thickness of the retinal nerve fiber layer (RNFL) possible (Figure la). 61 This method is based on the principle of using imaging polarimetry to detect the retinal nerve fiber layer, a method first described by Dreher in 1992.63 More specifically the operating principle of the Gdx is the measurement of the retardation (phase shift) of a polarized laser light passing through tissue possessing the physical property of form birefringence (such as the retina). Form birefringence is a phenomenon that occurs in tissue that is composed of parallel structures, each of which has a smaller diameter than the wavelength of the light used to image it. When a polarized light beam is impinged on a form-birefringent structure, the reflected light is split into two rays that travel at different velocities. This is due to small General Introduction 21  
parallel structures in the retinal nerve fibers that, being parallel to the retina, are essentially perpendicular to one of the polarization states and parallel to the other polarization state of the scanning laser beam. Only the perpendicular beam is essentially slowed down by the nerve fibers, which causes a difference between the two polarization states. This dif­ference in the two emerging rays, also called the phase shift between the two, is known as the retardation. In the RNFL, birefringence arises from the cylindrical structures several nanometers in diameter called microtubules contained within the individual nerve fibers. The greater the amount of nerve fiber tissue, the larger the number of microtubules and the greater the magnitude of retardation of the polarized laser light. This was demonstrated by Weinreb and colleagues who showed that retardation was linearly related to retinal nerve fiber layer thickness in hemisected fixated monkey eyes in which the cornea and lens have been removed. 64 Scanning laser polarimetry is, therefore, able to produce an indirect assess­ment of the thickness of the RNFL. Gdx results are displayed graphically on a false color map with blue colors in areas with little retardation, and red and yellow colors in areas with more retardation. The measurements obtained with this technique have been shown to be reproducible and to be capable of differentiating patients with glaucoma from glaucoma suspects or normal patients. One advantage of the GDx is that it was specifically designed for the detection of the retinal nerve fiber layer cells in contrast to, for instance, the OCT. A clinical example illustrates this best. In anterior ischemic optic neuropathy, the acute phase is often accompanied by edema of the retinal nerve fiber layer, but the axons of the nerve fibers are still intact; after three months, retinal nerve fibers start to degenerate and the edema has disappeared. An OCT scan in the early phase shows a thickened nerve fiber layer because of the edema, while a GDx in the acute phase does not show any difference from normal.65•66 After three months, both OCT and GDx show nerve fiber loss. One drawback of scanning laser polarimetry is that the new versions are not backwards compatible, which makes long-term follow-up of patients difficult. Another drawback of polarimetry itself is that microtubuli in the nerve fiber layer are not the only structures in the eye that cause retardation. Both the cornea and, to a lesser extent the crystalline lens, are capable of displaying form birefringence. 67 An anterior segment compensator was incorpo­rated into the design of the GDx in order to adjust for this polarization effect of the anterior segment. In all but the latest release of the GDx, this compensation was fixed and assumed a corneal polarization direction of 15 degrees nasally downward and a magnitude of 60 nm. The fixed compensator has been shown to be adequate for only about thirty percent of the population, due to inter-individual variation in corneal birefringence.67 This may lead to erroneous measurements in a significant number of people. 22 Chapter 1 
Visual field examination The classic description of the visual field given by Harry Moss Traquair is an island hill of vision in a sea of darkness. For purposes of clinical perimetry, the field of vision is usually regarded as the inner surface of part of a hemisphere. On this hemisphere the level of vision is determined from the point of fixation of gaze through the use of targets of various sizes and brightness. The level of the visual field is determined by the ability just to see a certain test object (or more accurately to be able to see an object for the fifty percent of the times when it is presented).68 This is called the threshold for that area and is determined by peri­metry. Perimetry is the systematic measurement of visual field function. Two approaches of perimetry are kinetic perimetry and static perimetry. Kinetic perimetry The first practical application of kinetic perimetrywas developed in 1945, when Goldmann of Bern devised a hemispheric bowl with a self-illuminated, projection perimeter (Figure 16).68 In this bowl, fixation, retinal adaptation, and stimulus size and intensity could be precisely controlled. The visual field could be readily recorded by means of an ingenious pantograph. With Goldmann or "kinetic" perimetry, a trained perimetrist moves the stimulus while stimulus brightness and size is held constant. This stimulus is moved from the periphery to the center of the visual field. The patient has to press a button when he is able to see the stimulus. This maneuver is performed a number of times over the entire perimeter of the visual field. Then a line, or isopter, is drawn on the chart of the visual field to represent the limit of the area within which a specific stimulus can be recognized. The limits of the visual field are subsequently mapped to stimuli of different sizes and brightness, creating a map of the entire field of vision. For almost half a century, Goldmann kinetic perimetry has been the standard visual field examination for all types of disorders. Goldmann perimetry has held this position for such a long time because of the ingenious design of the perimeter, coupled with smart detection tactics. In 1971 Armaly and Drance developed screening tac­tics for glaucomatous visual field defects, where stimulus presentation was concentrated in areas where glaucomatous damage was to be expected. One major drawback of Goldmann perimetry is that it requires an experienced operator to be performed. 68 Second, there is an inter-operator variability, which makes detection of changes on follow-up exams diffi­cult. However, because Goldmann perimetry is comparatively easy to perform and because Goldmann perimetry maps the entire field of vision, there are still several instances when Goldmann perimetry is used as a diagnostic tool. Currently there are several computerized kinetic perimeters in development. These aim to combine the advantage of a kinetic map of the entire visual field with reduced operator dependency. The best known of these perimeters is the Tiibingen kinetic perimeter. General Introduction 23 
Static automated perimetry Static automated perimetry (SAP) was introduced in 1975, when advances in technology made the automated presentation of stimuli possible. 69•70 In static automated perimetry, the visual field is mapped by presenting non-moving (static) stimuli of one size at various locations throughout the visual field. The brightness of the stimulus is varied until the dim­mest target the patient can see at each of the test locations is found. The threshold values for each location are shown on a map of the visual field. The advantage of the computerized systems for static automated perimetry is that they have eliminated operator dependency. In addition, a normative database can be stored in the perimeter. This normative database allows for immediate comparison of an individual's results to age-matched normal ones, and the results of this comparison are displayed on the printout as well. 68 This greatly simplifies the diagnosis of visual field results. Currently, virtually all ophthalmic practices in the Netherlands are equipped with a static automated perimeter, and static automated perimetry is the standard visual field test in the world for most indications. The two most common perimeters are the Humphrey Visual Field Analyzer (Carl Zeiss Meditec AG, Jena, Germany, Figure le) and the Octopus Perimeter (Haag Streit AG, Bern, Switzerland). Differences between the two perimeters lie in the testing grid used, and the amount of stim­ulus and background luminance.71 In addition, the two different perimeters offer slightly different parameters on the printout. However, static automated perimetry also has its drawbacks. The main drawback is that the test is difficult to conduct for patients. This problem originates in the goal of the test (i.e., determining the stimulus that is seen half of the time). This implies that half of the time a patient is looking at stimuli he can barely see; the other half of the time, stimuli are pre­sented that cannot be seen at all. For this reason, inattention and fatigue frequently com­promise results and most patients experience a learning curve. Two or three examinations are necessary before any conclusion can be drawn from a visual field examination. A second drawback is that static automated perimetry was designed specifically for the diagnosis and follow-up of glaucoma patients. Therefore, no classification system with unambiguous diagnostic criteria for every type of visual field defect has ever been developed. Third, the most commonly used SAP programs test the central 30 degree of the visual field, the most interesting part of the visual field in glaucoma patients, but it is largely unknown whether omitting to test the remainder of the spectrum of the field of vision leads to peripherally located visual field defects that are due to other disorders, being missed. Other types of perimetry Several additional types of perimetry have been developed over the years. Most of these types of perimetry use stimuli that are specially designed to be detected by a subset of 24 Chapter 1 
retinal ganglion cells. If one could effectively isolate a subset of retinal ganglion cells with reduced redundancy, this would theoretically enable one to detect abnormalities at an ear­lier stage. The best known of these types of perimeters are blue-on-yellow perimetry, rarebit perimetry, flicker perimetry, high-pass resolution perimetry, motion detection perimetry, direct projection perimetry and frequency doubling perimetry.71-77 The best known and most widely used among them is frequency doubling perimetry. This type has emerged over the last fifteen years and is used often in screening for glaucoma. Frequency Doubling Perimetry Frequency Doubling Technology (FDT)  perimetry is based on a phenomenon described by Kelly about forty years ago; he observed that when an achromatic sinusoidal grating of low spatial frequency undergoes counterphased flickering at a high temporal frequency, the apparent spatial frequency of the grating appears to be doubled.78 He reported that this occurred for sinusoidal gratings having a spatial frequency of less than approximately 3 cycles/degree, undergoing a counterphase flickering at a temporal frequency greater than 7 Hz. Maddess and Henry reported that the frequency doubling illusion could be useful in detecting glaucomatous field loss. Theoretically the FDT stimulus predominately stimulates the magnocellular ganglion cell pathway, which is primarily involved in motion detection and flicker detection.79 Some believe that the neurophysiological substrate for the frequency doubling illusion in humans lies in a subgroup of M cells, the proposed My cells, which show nonlinear characteristics for contrast and are thought to be preferentially lost in early glaucoma.79 Others question the mere existence of these cells in humans (based on histo­logical and physiological studies) and believe this illusion may be due to a more complicated processing that goes beyond a retinal level. 80 Irrespective of these different views, the FDT procedure has been shown to be clinically useful. FDT testing has demonstrated high sensitivity and specificity to early glaucomatous defects. 81 The clinical version of the FDT perimeter utilizes a vertical sine wave grating of low spatial frequency (0.25 cycles/degree) that undergoes counterphase flickering at a high temporal frequency (25 Hz). The contrast in the stimulus is modified using a staircase procedure for each of the locations (17 or 19) in the visual field (VF). 10° x 10° targets are used, 4 per quadrant within the central 20°, along with one smaller central target (5° diameter circle) projected on the macular region to measure contrast sensitivity. The major advantage of the frequency doubling perimeter is its ease of use. The large low-spatial frequency targets are not significantly affected by refractive errors of up to 6 Diopters, so optimal near correction is not needed. 8 1  The test takes about 4 to 5 minutes, depending on the presence and severity of VF defects, which prevents fatigue in patients and allows for reproduction of test results in the same visit. 8 1  The large targets also ensure that there is no clinically significant learning effect. 82 After the FDT perimeter (Welch Allyn, Skaneateles, N.Y., and Carl Zeiss Meditec, Dublin, Calif., General Introduction 25 
FIGURE I .  Pictures of the devices used in this thesis with an example of their output. From top to bottom of the page the GDx Nerve Fiber Analyzer (la), the Goldmann kinetic perimeter (lb), the Humphrey Field Analyzer (Jc) and the Frequency Doubling Perimeter (FDT; Id). lA 1B lC 1D 26 Chapter 1 . : : : :: : : . -�;.�.�!: :� ... L • • ,.  • & . J : ,  . I : : : :I :: :; · _(�.t.\ . .  r ,  r � -J -- 1 • LEFT EYE Teo! Dural)or, 0 51 ···-FIXATION ERRS O 13 FALSE POS ERRS O 1 3  Total 0ev'8bon P <  1% P < 0.5% Not aeen at maximum 
Figure ld) was launched commercially in 1997, it quickly gained popularity because of its ease of use. However, the claim of early detection of glaucoma could not be substantiated. A second drawback of the PDT perimeter is that, when it was launched, although a myriad of different algorithms for judging PDT results had been developed by research groups, there was no consensus on the best way to judge PDT results. Therapy for glaucoma According to the European Glaucoma Society the goal of glaucoma treatment can be sum­marized as follows: preservation of visual function adequate to individual needs with min­imal or no side effects for the expected lifetime of the patient without any disruption to his normal activities and at a sustainable cost.7 Although glaucoma is a heterogeneous disorder, increased intraocular pressure is the main risk factor for the development of glaucoma and currently the only factor amenable to therapy. Many randomized clinical trials have shown the efficacy of reducing intraocular pressure for the prevention of glaucoma in patients with ocular hypertension and for preventing or slowing the progression of glaucomatous visual field loss that has already occurred. 29-34 lntraocular pressure reduction can be accomplished in three ways: by the use of intraocular pressure-lowering drugs, by laser therapy and by glaucoma surgery.7·8 Since these last two entities fall beyond the scope of this introduction, the following sections will focus on pharmacologic therapy for glaucoma. The introduction of adequate drug treatment dates back to the second half of the nine­teenth century when almost simultaneously Weber advocated the use of the extract of jabo­randi (pilocarpine) and Laqueur that of the Calabar bean (physostigmine). 1 While the use of miotics has been the mainstay of antiglaucomatous therapy for over a century, other agents have been added to the pharmacological armamentarium. Administration of sym­pathomimetic drugs was performed for the first time around 1900 by Darier. 1 Osmotic therapy was used for the first time in 1904 by Cantonnet who administered sodiumchlo­ride.1 Carboanhydrase inhibitors were used initially by Becker in 1954.1 Alpha-agonists were discovered in 1969 and topical timolol, a beta-blocker, was introduced in 1978. 83 Topical carboanhydrase inhibitors were introduced in 1995 and topical prostaglandin ana­logues in 1997. 83 Current pharmacological options for glaucoma treatment can be divided into four groups based on their mechanism of intraocular pressure reduction. - Therapeutics that decrease intraocular volume - Therapeutics that increase aqueous outflow - Therapeutics that decrease aqueous production - Therapeutics that increase aqueous outflow and decrease aqueous production. General Introduction 2 7 
Therapeutics that decrease vitreous volume The osmotic agents, of which mannitol is the most frequently prescribed, is the only class of medication that decreases the volume of the vitreous body. These medications are only prescribed to patients who are hospitalized because of the extremely high intraocular pres­sures induced and because of the severe systemic disregulation that can occur. Therapeutics that increase aqueous outflow Therapeutics that increase aqueous outflow include the former first-line drug pilocarpine. This parasympaticomimetic drug acts by constricting the pupil and thereby opening the trabecular meshwork and thus increasing outflow.7•8•83 Because of side effects, that is, a reduction of the visual field because of the resultant miosis and reduction of visual acuity because of excessive accommodation, their use has diminished greatly over the last twenty years, since newer agents with fewer side effects have become available. The second class of drugs to increase outflow is one of the current first-line class of drugs, the prostaglandin analogues. After their introduction in 1997, their use has increased greatly, because of a large potential for intraocular pressure reduction accompanied by only mild side effects. 83 The most common side effects are eyelash growth, ocular surface irritation and darker iris color. A recent meta-analysis has shown that prostaglandin analogues reduce intraocular pressure by thirty percent on average. However, because prostaglandin analogues can in theory promote inflammatory activity, their use has been restricted for inflamed eyes; pros­taglandin analogues can cause macular edema. Due to the relatively recent introduction of prostaglandin analogues, real long-term data on their side effects are currently lacking. Therapeutics that decrease aqueous production The initial drugs that decreased aqueous production were the carboanhydrase inhibitors. In the 1950s the systemic variant became available; in the 1990s the first topical variant was introduced. 83 Systemic carboanhydrase inhibitors, although powerful intraocular pressure­lowering drugs, are currently reserved for refractory glaucoma cases because of their sys­temic side effects. Most patients experience only mild side effects such as tingling of the fingers, but there is a large group that has more severe gastrointestinal problems, is severely fatigued or even depressed. In addition carboanhydrase inhibitors may induce metabolic acidosis and electrolyte imbalance. The topical carboanhydrase inhibitors are generally well tolerated, but are not as efficacious in reducing intraocular pressure and are mostly used as adjunctive drugs. 28 Chapter 1 
Therapeutics that decrease aqueous production, topical beta-blockers The concept of adrenoreceptors dates back to 1948 when Ahlquist concluded that there were two distinct types of adrenergic receptors in the autonomic nervous system, which he called alpha and beta.84 This novel idea was adapted in 1958 by James Black, a pharma­cologist in search of a therapy for angina (heart disease caused by a restriction of oxygen supply due to arterial disease). 85 At that time the main aim was to improve myocardial oxygenation by prescribing vasodilatators. However, these vasodilatators had many side effects such as flushing and headaches, or were simply not effective. After reading Ahlquists concept of beta-receptors and their presence in the heart, Black hypothesized that a better approach would be to reduce the heart's oxygen demand, which could theoretically be done by administering beta-blockers. The discovery of beta-blockers was aided by the work of Powell and Slater, who published a report in 1958 about dichloroisoprenaline (DCI), 85 an analogue of isoprenaline developed by Eli Lilly as a possible long-acting bronchodilator. Instead of acting like isoprenaline, however, DCI had the opposite effect: that is, antago­nism. Black and a co-worker Stephenson quickly prepared DCI for testing, and applied it to a number of bioassays. Dichloroisoprenaline is now classified as a partial agonist, and its properties as such soon became apparent, with very tissue-specific effects in vitro. Although DCI was not the compound that was sought after, it did lead to the synthesis of a com­pound based on it, Imperial Chemicals Industries compound ICI 38,174, later known as pronethalol. Pronethanol antagonized the myocardial beta adrenergic receptors, but not the peripheral alpha receptors. Simultaneous clinical investigation yielded the same results in human beings, and demonstrated that pronethalol decreased heart rate and increased exer­cise tolerance in people with angina. Pronethalol itself never came into widespread clinical use; it was found to produce thymic tumors in mice and was discarded in favor of a similar but safer compound, ICI 45,520.85•86 Imperial Chemicals Industries compound ICI 45,520 would later be called propranolol.87 Propranolol was officially "launched" in 1964 under the trade name Inderal, and changed the face of cardiovascular medicine. 85•86 In 1967 it was observed that intravenous propanolol not only lowered blood pressure in hypertensive patients, but also lowered their intraocular pressure. 88 A number of cardio­vascular beta-blockers were subsequently evaluated for ocular hypotensive efficacy, notably atenolol, pindolol and bupranolol. Adverse side effects limited the use of early beta-blockers. 83 Proponalol, which possesses membrane stabilizing activity, caused significant corneal anesthesia. Practolol another systemic beta-blocker induced an immunologically mediated oculomucocutaneous syndrome, including eczematous rash, keratoconjunctivitis sicca and corneal ulceration. Atenolol showed disappointing long term results with almost complete tachyphylaxis after six months. Thus, research focused on a beta-blocker possessing the ocular hypotensive effect without the undesirable side effects and led to the development of timolol. Since the 1978 launch of timolol, a number of topical beta-blockers have been General Introduction 29 
developed. Several selective beta 1 blockers have been developed to reduce pulmonary side effects; these selective beta-blockers are not used much because their intraocular pressure lowering effect is less than that of nonselective beta-blockers. 83 The same is true for beta­blockers with an intrinsic sympathecomimetic effect, which were promoted as having fewer effects on cholesterol metabolism. 83 Today topical beta-blockers are, together with the prostaglandins, the first-line drugs in the treatment of glaucoma, with an average intraocular pressure reduction of about twenty­seven percent equal efficacy.90 The exact mechanism of action of beta-blockers remains unknown; however, it is known that they reduce aqueous production. 83 This makes them suitable for use in conjunction with other antiglaucomatous agents and beta-blockers are part of every fixed-combination antiglaucomatous eyedrop that is currently available. One of the main reasons that prostaglandin analogues are currently prescribed more fre­quently than topical beta-blockers is the reputation for side effects that beta-blockers pos­sess. The first report of side effects from topical beta-blockers stems from 1979, when topical pindolol was found to reduce exercise tachycardia in healthy volunteers.90 This was followed by a report by Van Buskirk in 1980 in which 547 reports of adverse reactions to timolol maleate, received by the National Registry for Drug-induced Ocular Side Effects, were described.91  The main side effects were bronchopulmonary obstruction and bradycardia. The first near fatal bronchospasm attributed to timolol was described in 1981.92 These side effects can only occur when there is significant systemic absorption after topical administration of a beta-blocker. The amount of timolol in one drop of 0.5% solution is about 1 mg. In contrast, the oral dose of timolol maleate for the treatment of hypertension is 20 mg to 40 mg per day. 83 The conjunctiva! cul-de-sac can hold an approximate 7 to 11 microliters of volume. 83 The size of an eyedrop varies between 30 and 80 microliters. 83 Thus, a large part of the medication is lost within the first few moments of administration, either by running down the cheek of a patient or by passing through the nasolacrimal drainage system. This latter method of absorption is significant, because by this route the absorbed drug enters the systemic circulation, avoiding the first-pass hepatic metabolism, which is quite relevant for beta-blockers. 83 Oral beta-blockers undergo an extensive first­pass metabolism with ninety percent of the drug inactivated by the liver so that relatively little of the drug reaches the systemic circulation. 83 In this respect, topical administration of beta-blockers is akin to intravenous administration, with higher drug plasma levels rela­tive to their starting dose being achieved. This may explain the possibility of systemic side effects for topical beta-blockers. 30 Chapter 1 
However, it should be noted that in the early years after timolol arrived on the market, there were fewer classes of antiglaucomatous drugs and the drugs that were available (pilocarpine and systemic carboanhydrase inhibitors) had such a bad side-effect profile that timolol was used in many patients, even those with asthma or preexisting bradycardia.93 This may have led to the overly negative image of beta-blockers. The newest beta-blockers are nonselective beta-blockers in gel formulas, so they can be applied once a day, which possibly reduces their systemic effects. Therapeutics that increase aqueous outflow and decrease aqueous production This group contains the alpha-adrenergic agonists and nonselective adrenergic agonists. The nonselective adrenergic agonists were used as early as 1900 by means of subconjunctival injection and by 1923 they were administered topically.1 Their use has greatly diminished with the advent of newer classes of drugs, because over fifty percent of patients who used these nonselective adrenergic agonists became intolerant to them. The selective alpha 2-ago­nists are currently used as second line drugs, also because of the high percentage of patients that become intolerant to this class of medication and, in addition, because the percentage of intraocular pressure lowering is not as high as that of prostaglandin analogues and beta­blockers. Other potential targets for glaucoma therapy Because lowering intraocular pressure cannot restore visual field defects that have already developed and because there are patients progressing despite adequate control of intraoc­ular pressure, much research has focused on other targets for antiglaucomatous therapy. Potential target sites for neuroprotection that have been evaluated are NMDA receptor antagonists. The NMDA receptor when activated facilitates calcium influx into the cell and thereby promotes apoptosis. 25 As apoptosis appears to be the most important mechanism for ganglion cell death in glaucoma, the NMDA receptor seems a viable target for inhib­iting this process. Recently a large randomized clinical trial evaluating the use of meman­tine, an NMDA receptor antagonist, was concluded. It showed no beneficial effect from the administration of memantine for glaucoma.94 Other studies of potential targets for neuroprotection, mainly based on the vascular theory of glaucoma, have focused on trying to improve blood flow to the optic nerve. In this light, several case series have been published that have found a slight improvement in visual fields in patients who were using calcium-channel blockers.95•96 The vasodilatating properties of the calcium-channel antagonists were thought to improve blood flow to the optic nerve. General Introduction 31 
However, all of these case series lack significant follow-up and lack significant numbers of visual field examinations as well. Systemic beta-blockers, on the other hand, were thought to reduce blood flow to the optic nerve and, as a consequence, it was implied that systemic beta-blockers might worsen existing glaucoma.97 Although low systemic blood pressure was implicated in the develop­ment of glaucoma as early as 1972 by Drance,56 the first report specifically linking anti­hypertensives to glaucoma was published in 1979 by Alm.98 After this report several other mostly small studies followed; these suggested that several classes of antihypertensives, especially beta-blockers could exacerbate glaucoma. Outline of this thesis This thesis is bipartite and describes studies on both diagnostic and therapeutic controver­sies in the field of glaucoma. The first part of this thesis consists of three chapters that focus on methods for improving the diagnostic instruments used for the detection of glaucoma. In Chapter Two the controversy surrounding the most commonly used static automated perimeter in use today, the Humphrey Field Analyzer (HFA), will be addressed. This perimeter was designed for the detection and follow-up of glaucoma, but was soon used for many other disorders. Even after many years of use, there is no consensus on the way to define a glaucomatous visual field defect using the HFA, nor is there any consensus on definitions of other visual field defects using the HFA. In Chapter Two, we will describe the development and testing of an unambiguous scoring system for all types of visual field defects using the HFA. FDT was introduced onto the market in 1997 as a glaucoma screening device; however, a clear definition of an abnormal visual field was not provided with the machine. In Chapter Three, all published algorithms classifying an FDT visual field will be compared. The GDx fixed anterior segment compensator is only correct in twenty-eight percent of indi­viduals. Variable anterior segment compensators cannot be retrofitted onto older models of the GDx. In Chapter Four, we will investigate whether the diagnostic performance of the GDx with fixed corneal compensation can be improved by taking the results of the macular scan (a measure of accuracy of the anterior segment compensator of the instrument) into account. The second part of this thesis will focus on the effects and possible side effects of both sys­temic antihypertensives and topical beta-blockers. 32 Chapter 1 
Systemic hypertension and its treatment have been implicated in the development of glau­coma for a long time. Reduction of blood flow to the eye, resulting from the treatment of hypertension, may adversely affect the development of glaucoma. Beta-blockers especially are thought to reduce blood flow to the eye and cause glaucoma. This is peculiar, because topical beta-blockers are a first-line treatment for glaucoma. In Chapter Five, we will inves­tigate the effect of the use of systemic beta-blockers and other antihypertensives on the development of glaucoma. Although beta-blockers are the mainstay in the treatment of cardiovascular disorders, sev­eral studies imply that the use of topical beta-blockers increases the chance of cardiovascular mortality. In Chapter Six, the results of a study into the safety of topical beta-blockers will be presented. The main question to be answered in this chapter is whether the use of topical beta-blockers does increase mortality. General Introduction 33 
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Abstract Purpose: To develop a classification system for the entire spectrum of visual field (VF) loss (VFL) on static automated perimetry (SAP) and to evaluate this system using data from a population-based study. Design: Population-based cohort study. Participants: 3842 participants of the Rotterdam Study, aged 55 years and older, of whom data from ophthalmologic examinations were available. Methods: All participants underwent VF screening with supra-threshold SAP; those with a reproducible abnormal or unreliable screening test result (n=282) underwent both full­threshold SAP (Humphrey Field Analyzer 24-2) and Goldmann perimetry by experienced perimetrists. A classification system for all types of VFL on SAP was developed independ­ently from these VF  data. The full-threshold SAP test results were classified according to this new SAP classification system (SAPCS); the results were compared to the presumed cause of VFL and to Goldmann perimetry results. The presumed cause of VFL was deter­mined using all available data (fundus photography, results from ophthalmic and neuro­logic exams, patient files, etc.), excluding the full-threshold SAP test results. Results: Reliable full-threshold SAP and Goldmann data were available for 264 right eyes and 262 left eyes of 268 participants. Classification of the full-threshold SAP test results with SAPCS was feasible in all eyes. Agreement between Goldmann kinetic perimetry and SAPCS was moderate; SAPCS was in line with the final diagnosis in the majority of cases. SAPCS identified more VFL than Goldmann perimetry (OD: 216/264 versus 136/264, 
P < 0.001; OS: 214/262 versus 154/262, P < 0.001). The most frequently observed differ­ence was an arcuate scotoma with SAPCS and no VFL with Goldmann. Conclusion: SAPCS seems a promising method for classifying visual field defects on static automated perimetry. Patterns of Visual Field Defects on Standard Automated Perimetry Defined 43 
Introduction Since the introduction of static automated perimetry (SAP) in 1975, it has rapidly become the most frequently used technique for visual field (VF) examination for virtually all pur­poses.1-4 Advantages over kinetic perimetry are the easier quantification of visual field loss (VFL), its presumed better sensitivity for early stages of diseases like glaucoma and its reduced dependency on skilled operators.5 Since glaucoma-related testing constitutes the vast majority of VF testing in clinical practice, the literature on the interpretation and quantification of abnormal SAP test results mainly focused on glaucoma. 6 However, it has been shown that virtually all neuro-ophthalmic VFL on Goldmann kinetic perimetry can be detected as well with SAP limited to 30° eccentricity.7 Moreover, SAP has been incorporated as the default perimetric tool in most ophthalmic practices in many countries. Therefore, we considered the development of a consistent set of SAP definitions for all types and causes of VFL long overdue. In this study, we present an algorithm for a systematic evaluation of SAP test results, using a scotoma definition commonly used in glaucoma as a starting point. 8 This algorithm, which we named SAP test result Classification System (SAPCS), should allow for an easy and unambiguous classification of any SAP test result, both in research and in clinical practice. Although we aimed to make it as independent as possible of specific software or devices (for that reason, for example, we did not include the glaucoma hemifield test), in the cur­rent study we focused on the 24-2 grid of the Humphrey Visual Field Analyzer (HFA; Carl Zeiss Meditec AG, Jena, Germany). 8 SAPCS was subsequently tested in a large population-based cohort in which perimetry was performed with both SAP and Goldmann perimetry. The testing of SAPCS had two goals. First the feasibility of the algorithm was tested by judging if it was possible to apply the algorithm in all SAP VFs and by determining inter-observer agreement. Second, the diag­nostic performance of SAPCS was tested. Obviously, a real gold standard is lacking here. We compared SAPCS with Goldmann perimetry, although at most a moderate agreement was to be expected (see Discussion). For that reason we primarily focused on a comparison of SAP CS with the presumed causes of the observed visual field loss. These causes of VFL were determined as part of an earlier study,9 using the Goldmann test results and all other available information (except for the SAP test results).9 44 Chapter 2 
Methods 
Study Population The study population of the present study consists of participants in the Rotterdam Study, a prospective population-based cohort study of all residents aged 55 years and older living in the Ommoord suburb of Rotterdam.10 The study protocol was approved by the Medical Ethics Committee of the Erasmus University and all participants provided written informed consent in accordance with the Declaration of Helsinki. The baseline examination of the Rotterdam study took part in 1990-1993. Of the original eligible cohort of 10,275 individuals, 7983 persons (78%) participated in the study. Because the ophthalmic part of the Rotterdam study started no earlier than 1991, only 6971 of 7983 (87%) participants were included in the ophthalmic part of the Rotterdam study. Because at baseline Goldmann perimetry but no full-threshold SAP testing was performed, the current study is based on 3842 participants who took part in the ophthalmic follow-up examination from 1997 to 1999. These 3842 participants underwent a full ophthalmological examination including supra­threshold VF screening, followed by both full-threshold HFA 24-2 testing (Humphrey Field Analyzer 720; Carl Zeiss Meditec AG, Jena, Germany) and Goldmann perimetry (Haag Streit AG, Koeniz, Switzerland) by perimetrists with 5 or more years experience in Goldmann perimetry in those with a reproducible abnormal or unreliable screening test result.9 
Classification of Goldmann perimetry results The presence and type of defects on Goldmann perimetry were determined in earlier studies by four independent graders.9• 1 1  Classification categories used in that study were central island, temporal island, central scotoma, paracentral scotoma, ring scotoma, ceco­central scotoma, enlarged blind spot, arcuate scotoma, nasal step, temporal wedge, scotoma unspecified, homonymous anopia (hemianopia, quadrantanopia and other homonymous defects), and altitudinal defect. 
Determination of the cause of visual field loss Because of its relevance to the current study the process of determining the cause of V FL will be presented here in some detail, although it was part of earlier studies.9• 1 1 For the assessment of the causes of VFL, two ophthalmologists (PTVMdJ and RCWW) independently determined whether and where VFL was to be expected based on the pres­ence and location of abnormalities on fundus photographs. To prevent bias, images of both eyes of cases with VFL in either eye were examined, regardless of the presence or absence Patterns of Visual Field Defects on Standard Automated Perimetry Defined 45 
of VFL. The examiners were at that time unaware of the outcome of perimetry and other clinical data. Next, the examiners looked at the Goldmann VFs and checked if the location and cause they had predicted agreed with the outcome of perimetry. For cases in which fundus signs did not correspond with the Goldmann VFs or no cause could be found, information from the ophthalmological examination at the study center was used as well as ophthalmological and neurological information from medical records from hospitals and general practitioners. All discordant outcomes were discussed between the two examiners to determine the definite cause. During the whole process of identifying the cause of visual field defects the examiners had no access to the full-threshold SAP data. 
A SAP test result Classification System (SAPCS) We used as the base of SAPCS the presence or absence of a scotoma in either the total deviation probability (TD) or the pattern deviation probability (PD) plot. A scotoma was defined as the presence of three adjacent points with a sensitivity P < 0.05 of which at least one point P < 0.01.8 Two of these three points had to be next to each other in horizontal or vertical direction; the third point was allowed to be "diagonally" adjacent. The points had to be in the 24-2 grid of the HFA. Hence, in case of a SAP device with an evenly spaced 6x6° grid pattern testing up to 30°, the edge points with the exception of the two most nasal points have to be omitted. Figure 1 outlines the SAPCS algorithm. The major steps are the following. Step 1: Determine if the VF  test results are reliable. We considered a VF unreliable if false-positive catch trials exceeded 33%. A VF was also considered unreliable if both false-negative catch trails exceeded 33% and fixation losses exceeded 20%. Obviously, the criteria depend upon the perimeter used and the strategy applied. For example, with one of the SITA-strategies these percentages could be changed to 20% for fixation losses and 10% for false positives and false-negatives. Step 2: Determine if there is any abnormality. For this, the scotoma definition as outlined above should reveal a scotoma in the TD plot in at least one eye. If there is no sign of a scotoma in the TD plot, the VF is classified as normal. Step 3: In case there is any abnormality (as determined in step 2), decide if it is possible to discern a pattern of VFL. No pattern of VFL can be defined if there is either too much or too subtle VFL. By definition, this is the case if either more than 85% of the VF in the TD-plot is 46 Chapter 2 
abnormal (that is, fewer than eight points on the HFA 24-2 grid are normal) or if there is no scotoma on the PD plot. In both cases, the outcome of SAPCS is "General reduction of sensitivity". 
Step 4: Apply the remainder of the algorithm as displayed in the flow diagram in Figure 1. Patterns of visual field loss are studied in the PD plot. First, homonymous and bitemporal abnor­malities are evaluated, followed by abnormalities of the anterior visual pathways. The defi­nitions applied were based on the Tiibingen classification system. 1 1  The number of different patterns was kept as low as possible to facilitate the ease of use of the system. For instance, no attempt was made to subdivide either homonymous or bitemporal anopias into hemi­anopias and quadrantanopias. The classification system forces users to assign all VFL to only one pattern of VFL. This implies that more than one defect may be diagnosed in the same field. 
Step 5: Grade severity of VFL. For this purpose, the global index Mean Deviation (MD) was used. A mild defect was defined as an MD value of -6 dB or better, a moderate defect as worse than -6 dB but not exceeding -12 dB and a severe defect as worse than -12 dB. 
FIGURE I .  Outline of the Standard Automated Perimetry test result Classification System (SAPCS). Prior to applying this flow chart, reliability should be checked and the presence of any classifiable defect should be evaluated (see Methods). All definitions refer to the pattern deviation probability plot unless stated otherwise. Points may be present on the other side of the vertical or horizontal meridian, as long as they do not reach the minimum number of points required for defining a scotoma. If the abnormal points on the other side of the horizontal or vertical meridian form a scotoma themselves, they must be classified separately. Patterns of Visual Field Defects on Standard Automated Perimetry Defined 47 
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In case of an arcuate scotoma confined to the temporal side of the vertical meridian check the other eye for centraal scotoma or severe general reduction of 
sensitivity. Then diagnose as possible :mrcrior junction syndrome. 48 Chapter 2 
Evaluation of SAPCS One ophthalmologist (RPHM) classified all full-threshold HFA VFs according to our SAPCS algorithm. During the classification process, there was no access to either the supra­threshold VFs, the Goldmann VFs or to the clinical information on the participants. A second ophthalmologist classified a random subset of 100 threshold 24-2 HFA VFs of 51 participants to test inter-observer variability. This ophthalmologist, who did not participate in the development of the SAPCS, received 30 minutes instruction before classifying the VFs according to our SAPCS. The SAPCS was evaluated by dividing the number of correctly diagnosed participants with glaucoma, stroke or macular degeneration by the total number of participants with these disorders. Participants were considered to be diagnosed correctly by SAPCS if the type of VFL was compatible with the diagnosis. For glaucoma, an altitudinal defect, a nasal step, an arcuate scotoma, a concentric restriction of the visual field and a general reduction of sensitivity were considered compatible. For stroke, a homonymous anopia was considered compatible, and for macular degeneration, a general reduction of sensitivity, a central defect and a paracentral defect were considered compatible. Patterns of Visual Field Defects on Standard Automated Perimetry Defined 49 
Results Full-threshold HFA and Goldmann kinetic perimetry was performed in 282 of 3842 (7.3%) participants. Table 1 shows their baseline characteristics. Perimetry with either HFA or Goldmann, or both, was not possible in 14 right eyes and 14 left eyes, because these eyes had lost too much function to be testable. Of the remaining 268 right eyes and 268 left eyes of 278 participants, four (1.5%) right eyes and six (2.2%) left eyes had unreliable results on HFA perimetry and were excluded from further analyses, leaving 264 right eyes and 262 left eyes of 268 participants. Classification of the HFA VFs according to our SAPCS was possible in all these eyes. Table 1 Characteristics of the participants with abnormal suprathreshold visual field screening test results (n=282). Characteristics of the participants (n=282) Age (years) Gender (% female) Number of eyes with both full-threshold HFA and Goldmann visual field testing - OD 
- OS Unreliable HFA fields (%) - OD 
- OS Number of eyes included - OD 










-6.6 (5 .5) 
-7.9 (7.0) 
Mean (standard deviation) unless stated otherwise; HFA = Humphrey Field Analyzer; MD = Mean Deviation. Table 2 shows a comparison of VFL classification according to SAPCS versus Goldmann, for both OD (2A) and OS (2B). More cases showed VFL with SAPCS than with Goldmann (OD: 216/264 versus 136/264, P < 0.001; OS: 214/262 versus 154/262, P < 0.001). The most frequently observed finding was an arcuate scotoma with SAPCS and no VFL with Goldmann. An arcuate scotoma with SAPCS was most often classified with Goldmann as an arcuate scotoma or a paracentral scotoma, or as no defect. An arcuate scotoma with Goldmann was most often classified with SAPCS as an arcuate scotoma, followed by a general reduction of sensitivity. Most homonymous defects with SAPCS showed a sim-50 Chapter 2 
ilar classification with Goldmann. Some cases with hemianopia or quadrantanopia with Goldmann were classified as a general reduction of sensitivity or an arcuate scotoma with SAPCS (see Discussion). About half of the eyes with a general reduction of sensitivity with SAPCS were graded as having mild to moderate VFL (OD: 28 of 50; OS: 36 of 87). Most of these cases with mild to moderate VFL showed no abnormalities with Goldmann perimetry. Most cases with a severe general reduction of sensitivity showed abnormalities with Goldmann peri­metry and these abnormalities were classified as either an arcuate scotoma or a (para)central scotoma. Amongst this group, the most frequently reported diagnosis was glaucoma (13 of 32 participants). Table 3 shows a more detailed look at the severity of VFL on HFA versus the type of defect. A general reduction of sensitivity and arcuate scotomata were found in all severity catego­ries. Altitudinal defects resulted almost exclusively in severe visual field defects, while no participants with central scotomata, paracentral scotomata, or nasal steps were classified as having severe visual field loss. Table 4 shows the comparison between SAPCS and the causes of VFL for OD (4A) and OS (4B). Cases with glaucoma most often displayed an arcuate scotoma, sometimes a general reduction of sensitivity, an altitudinal defect, or a nasal step. Cases with stroke most often had homonymous anopia, sometimes an arcuate scotoma. Cases with age-related macular degeneration displayed a paracentral scotoma, a cecocentral scotoma, a central scotoma, a general reduction of sensitivity or an arcuate scotoma. Of the 41 participants classified with glaucoma as the cause of VFL in the right eye SAPCS classified 40 (98%) correctly. Of the 39 participants classified with glaucoma as the cause of VFL in the left eye SAPCS classi­fied 37 (95%) correctly. In participants classified with stroke as the cause of VFL, SAPCS classified 15 of 25 (60%) right eyes and 15 of 24 (63%) left eyes correctly. Six of 11 (55%) right eyes and 7 of 14 (50%) left eyes with visual field defects presumed to be caused by macular degeneration were classified correctly by SAPCS. The inter-observer variability of SAPCS was very small; 99 of the 100 VFs in 51 partici­pants were scored identical. The single VF that was not scored identical was a field with a small scotoma in the TD plot and none in the PD plot. This scotoma was not seen by one of the classifiers who classified the field as normal. The other classifier correctly classified the field as a general reduction of sensitivity. The second classifier, who was not involved in the development of SAPCS and received 30 minutes of instruction in SAPCS, classified all 100 fields in 1.5 hours. Patterns of Visual Field Defects on Standard Automated Perimetry Defined 51 
� Table 2 Classification of Goldmann visual field test results14 versus the classification 
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Discussion The classification system, SAPCS, that we have developed appeared to be easily applicable to all VFs in our population based study. The inter-observer variability was very low due to the unambiguous nature of the classification system and SAPCS was easy to learn and apply. The fact that the resulting classification was in line with the final diagnosis in the majority of cases further supports the use of SAPCS. Obviously, a perfect agreement between the pattern of VFL and the final diagnosis cannot be expected: various diseases may produce very similar VFL and vice versa. It should be emphasized that a diagnosis is not equivalent to a test result; rather, it is a compatibility with a disease based on the case history, an ocular examination and additional testing like perimetry and a neurological examination. Our study revealed only a moderate agreement between SAPCS and the classification of VFL with Goldmann perimetry. This is not an unexpected finding, given the differences in the underlying approach (static versus kinetic perimetry) and the eccentricity tested (24° versus the entire visual field). Advanced glaucomatous VFL, for example, may result in a general reduction of sensitivity with SAPCS, whereas with Goldmann perimetry more specific abnormalities still can be found. Likewise, optic neuritis tends to cause a central scotoma with Goldmann perimetry whereas SAP testing often reveals a general reduc­tion of sensitivity.1 2  Another possible source of different classifications between SAPCS and Goldmann perimetry lies in the way quadrantanopia and hemianopia were addressed. In the classification system for Goldmann perimetry that was used in the Rotterdam study, these abnormalities were allowed to be diagnosed monocularly (that is, a case could have a hemianopia in one eye and no VFL in the other eye),9 whereas with SAPCS a classification of hemi- or quadrantanopia required a bilateral field defect (that is, at least some overlap in both eyes). Advanced glaucomatous VFL in the upper nasal quadrant of one eye extending to the vertical meridian, for example, could be classified as a unilateral quadrantanopia on Goldmann perimetry whereas SAPCS would yield an arcuate scotoma. Full-threshold HFA appeared to detect more subtle VFL than Goldmann perimetry. Although this finding is in line with previous reports,S in our study it might be caused by the fact that the participants were preselected with supra-threshold static perimetry. This pre-selection might have caused a bias towards participants with abnormalities on static perimetry and therefore may artificially induce more VFL on static perimetry than on kinetic perimetry. We developed SAPCS not only for scientific purposes (where the need for unambiguous definitions is obvious) but also for clinical practice. Uniform terminology is - in the end -Patterns of Visual Field Defects on Standard Automated Perimetry Defined 55 
also beneficial for an individual patient (again, a classification of VFL is not a diagnosis). Another advantage of using SAPCS in clinical practice is that it forces the clinician to analyze the VFs of a patient in systematic way: addressing reliability first, followed by bin­ocular abnormalities and monocular abnormalities. This reduces the chance of overlooking important findings. Earlier classification systems aimed either solely at the diagnosis of glaucoma without including a classification for other types of VFL, 6 or aimed solely at VFL due to chiasmal or post-chiasmal visual pathway lesions (respecting the vertical meridian). 13 Simply com­bining these previously published systems was not possible because together they did not form a consistent set of definitions. The Tiibingen classification system, 12•14 allowed for the classification of both ocular and neuro-ophthalmological types of VFL and therefore we used this as a starting point for our SAPCS. Unlike the essentially descriptive Tiibingen system, however, SAPCS follows an obligatory sequence when analyzing VFs and defines the types of VFL unambiguously. Moreover, due to the much higher spatial resolution used in the Tiibingen system (more than 190 test locations within 30° eccentricity), the use of a threshold-related, slightly supraliminal strategy and the use of a polar grid (a variably spaced grid with more testing points near the center of fixation and wider spaces between testing points in the periphery), the Tiibingen system cannot be applied to HFA data just like that. When a new diagnostic tool is developed with the use of experimental data, it has to be tested in an independent dataset. It must be stressed that the algorithm as presented here was developed without the use of the data from the current cohort. Rather, it was developed by literature study and discussions amongst the authors before any evaluation took place, and no adjustments were made after the evaluation. SAPCS addresses a limited number of VFL patterns. For example, homonymous loss was restricted to homonymous anopia, leaving all defects such as homonymous hemianopia, quadrantanopia and rare patterns like a pie in the sky or a pie in the floor to be classified as a homonymous anopia.15 Figure 2 shows the spectrum of homonymous anopia. We restricted SAPCS on purpose to a limited number of commonly found VFL patterns because the lim­ited number of testing points (54) and the limited area of tested field (up to 24° eccentricity only) do not warrant a too detailed classification. An advantage of the limited number of VFL patterns in SAPCS is that SAPCS is easy to learn and apply in daily clinical practice. Whether or not it makes sense to test the peripheral field in the case of a high suspicion for abnormalities and a normal 24-2 VF cannot be concluded from this study. 56 Chapter 2 
FIGURE 2. Ihe spectrum of homonymous anopia. SAPCS does not make a division into subtypes of homonymous (and bitemporal) anopia. Ihis figure shows the entire spectrum of homonymous anopia, from mild (la) to quad­rantanopia (moderate; lb) to hemianopia {severe; Jc). 2A . I · I . .  , . .  • ■ ■  ■ ·  : : . ! - . · 1• i ■ ■ ■ . . . .  ■ ■ ■ ■ . . .  ■ ■ ■ · ■ ■  2B ■ ■  ■ ■ ■ ■ ■  ■ ■ ■  ■ ■  . . ■ ■ : : . ,: : : ■ 2C ■ ■ ■ ■ ■  . ,. i ■ ■ ■ . ■ ■ ■ ■  . .  ■ ■ ■ · ■ ■ • •  • • •  • • • •  ■ ■  ■ • •  ■ • • • •  ■ ■ ■ • •  Thus far, the terminology presented here was mainly directed towards HFA, the perimeter used in this study. It should be possible, however, to use SAPCS with other SAP perimeters. In fact, for this reason SAPCS was specifically designed to be independent of perimeter specific variables like the Glaucoma Hemifield Test. On Octopus perimeters (Haag Streit AG, Bern, Switzerland), for example, the equivalents of the TD plot and PD plot are named probability and corrected probability plot. Moreover, for grading purposes, the Octopus global index Mean Defect can be used with the same cut-off points as mentioned in the Methods, omitting the minus sign. SAPCS, however, cannot be used on Octopus perim­eters without modification since the Octopus perimeter uses, unlike HFA, a polar grid. The strength of our study is the design: a prospective, population-based study which ensures a realistic sample of patterns of VFL. Also, because of the design of the Rotterdam Study, a complete overview of each participants medication use and concurrent illnesses was available, enabling the determination of the cause of VFL as accurately as possible. Possible weaknesses were that participants underwent only one full-threshold HFA test. This could possibly lead to less accurate SAP results and does not address intra-subject variability. On the other hand, all participants underwent supra-threshold static automated perimetry twice prior to full-threshold static automated perimetry and, as a consequence, all had more perimetric experience than in most population-based studies and less than in most clinical settings. This was also demonstrated by the fact that the frequency of unreli­able SAP results was very low (1.5% and 2.2% for right and left eyes, respectively). One might argue that our criteria for reliability of the VFs were not very strict. 16 Recent reports, however, indicated that false-positive catch trials are by far the most important threat to reliability and therefore we pooled false-negative catch trials and fixation losses.17 A second drawback of the design of the study is that certain defects are relatively rare in the general population aged 55 years and older. For instance, no one was diagnosed as having lesions in the chiasm region or retinitis pigmentosa. However, the most frequently observed patterns Patterns of Visual Field Defects on Standard Automated Perimetry Defined 57 
of chiasm related VFL, bitemporal VFL and the anterior junction syndrome,18  should be covered by SAPCS, as should be defects due to retinitis pigmentosa (the latter defects will presumably be classified as a concentric restriction as the classical ring scotoma cannot be observed within 24° eccentricity). Further studies in selected populations should address these issues. In conclusion, a classification system for SAP was developed and tested in a population­based setting. The classification system proved to be easy to perform and robust, and the resulting classifications were in line with the final diagnosis in the majority of cases. 58  Chapter 2 
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Abstract All previously published algorithms for the interpretation of frequency doubling perimetry test results were compared in full-threshold mode in a large group of glaucoma patients (n = 452) and normal subjects (n = 237). Areas under the receiver-operating characteristic (ROC) curve ranged from 0.86 to 0.92. None of the algorithms performed substantially better than simply counting the number of defects P < l % in the total deviation plot. For this algorithm, we found a sensitivity of 0.90 and a specificity of 0.81 at a cut-off point of >1 defect, and an area under the ROC curve of 0.92. An Evaluation of Algorithms Designed to Classify the Results from PDT 63 
Introduction Glaucoma is a chronic disease that may cause irreversible blindness, but the early stages of glaucoma do not cause any symptoms. Treatment of glaucoma may arrest or slow down its progress.1 Therefore, screening for glaucoma might be advisable. Various studies have sug­gested that the frequency doubling perimeter (FDT) may be suitable for this purpose. 2•3•4 For every new test, one of the most important questions is how to interpret its results. Like the Humphrey Field Analyzer (HFA), FDT produces a mean deviation (MD), a pat­tern standard deviation (PSD), and total and pattern deviation plots. From these global indices and plots, several algorithms for the interpretation of FDT test results have been developed. The first published algorithms simply counted the number of defects on the total deviation plot. Quigley reported a sensitivity of 0.91 and specificity of 0.94 with a criterion of two or more missed points in C20-1 screening mode.3 Later, algorithms with a weight factor assigned to the location or the severity of the defect were developed. Patel et al. described the empirical development of such an algorithm with a sensitivity of 0.80 and a specificity of 0.93.5 There are also algorithms that depend upon the presence of two or more adjacent defects.6 Although many studies used two or three variants of one algorithm, there are only a few studies comparing different types (counting, weight factor, and clusters) of algorithms. Thomas et al. compared three algorithms and found that the best results came from the system developed by Patel et al.5-7 Another study comparing different algorithms by Trible et al. failed to find significant differences.6 Yamada et al. found no difference between a counting system and an algorithm that added weight factors to the severity of the defect. 8 The aim of the present study is to review all previously published algorithms and to com­pare these algorithms in one and the same large dataset of 452 glaucoma patients and 237 normal subjects. 64 Chapter 3 
Methods 
Patient data and study protocol The glaucoma patients incorporated in the present study were recruited from a large cohort that is currently followed prospectively with FDT and GDx (Nerve Fiber Analyzer; Laser Diagnostic Technologies, San Diego, CA, USA) in the glaucoma service of our outpatient department. In this cohort, 452 patients (242 males, 210 females) out of 1051 consecu­tive visitors to the glaucoma service were classified as glaucoma patients, based on conven­tional perimetry. Most of the time, we used the HFA 30-2 SITA-fast (Carl Zeiss Meditec AG, Jena, Germany). In some cases (mainly elderly subjects with advanced glaucoma), Goldmann perimetry (Haag Streit AG, Bern, Switzerland) was applied in addition to HFA. For HFA, a visual field defect was defined as a defect together with either GHT outside normal limits or PSD P < 0.05 or a scotoma defined as three adjacent non-edge points 
P < 0.05 of which at least one point P < 0.01 and with all points on the same side of the horizontal meridian (LTG-P criterion).9 Defects had to be compatible with glaucoma and without any other explanation. Patients with a reproducible visual field defect in at least one eye were considered to be (manifest) glaucoma patients. For Goldmann, a visual field defect had to be either a paracentral/arcuate Bjerrum scotoma, a nasal step, or a temporal rest and/or a central island. In addition to these 452 glaucoma patients from the glaucoma service, 237 normal subjects (118 males and 119 females) were recruited outside the hospital by advertising in local senior departments, among volunteers from the local blood bank, and in other public places. Subjects regularly visiting an ophthalmologist for glaucoma-related reasons were excluded. The normal subjects did not have perimetric experience. FDT, however, has at most a small learning effect. 10 Both in the glaucoma patients and in the normal subjects no (further) exclusion criteria were applied in order to get samples as representative as possible of the populations studied. The mean age of the glaucoma patients was 69 years (SD 14 years); the mean age of the normal subjects 63 years (SD 11 years). This difference is significant (P < 0.05). As we only used age-corrected FDT parameters, however, the confounding effect of age should be negligible. The worse eye of the glaucoma patients had a mean MD(HFA) of 11.5 dB (SD 8.6 dB). Normal subjects with an abnormal FDT test result were referred to an oph­thalmologist. Although the reports from these referrals are still far from complete, it is already clear that at most a small minority of these subjects has manifest glaucoma. This is in agreement with previously published prevalences of undetected glaucoma (typically 0.5%).11,12 An Evaluation of Algorithms Designed to Classify the Results from FDT 65 
Frequency doubling perimetry Testing was performed with the frequency doubling perimeter (PDT; Carl Zeiss Meditec AG) using the C20 full-threshold mode. The FDT stimulus is a low spatial frequency (0 .25 cycles per degree) sinusoidal grating with a high (25 Hz) temporal frequency. The test has 17 test locations; 16 square test locations of 10 degrees in size, four in each quadrant, and a round central test location, with a diameter of 5. During the test, a contrast threshold is determined for each of the test locations by means of a staircase procedure, the modified binary search (MOBS) . The patient's results are presented in a plot that shows the contrast sensitivity of the tested locations expressed as a dB value. By comparing the patient's results to an age-corrected normative database, total and pattern deviation plots are produced and the corresponding global indices MD and PSD are calculated. In the plots a threshold level that would be visible to 95% of normal subjects of the same age is considered normal and is indicated by a white color of the test location. There are four abnormal threshold levels, P < 5%, P < 2%, P < l %, and P < 0.5%, for which the probability is, respectively, less than 5%, 2%, 1% and 0.5% that a normal subject would have the threshold level of this patient. FDT was performed in both eyes, and a patient was considered positive if there was an abnormal test result (according to the algorithm investigated) or an unfeasible test in at least one eye . All normal subjects were able to perform the test. In the glaucoma patients, the test was unfeasible in 48 out of 452 patients . The technology of PDT is such that the right eye, if qualified, is always tested firstly. In case of only one functional eye, only that eye was used for classifying the patient and for determining the test result. For details on frequency doubling perimetry, see e.g. Maddess and Henry (1992); Johnson and Samuels (1997), and Maddess et al . (1999) . 2• 13• 14 Algorithms and analysis There are 15 different published algorithms: (1) The number of defects anywhere in the field (Quigley, 1998) .3 (2) The number of non-central defects anywhere in the field (Trible et al ., 2000) . 6 (3) The number of defects in the superior hemifield (Bowd et al ., 2001) .15 (4) The number of defects in the inferior hemifield (Bowd et al ., 2001) . 15 (5) The presence of two adjacent defects anywhere in the field (Thomas et al., 2002) .7 (6) The presence of two adjacent non-central defects P < 1% in one hemifield (Trible et al ., 2000) .6 (7) The presence of three or more defects depressed to the P < l % level or six or more defects depressed to the P < 2% level (Burnstein et al ., 2000) .16 66 Chapter 3 
(8) A grading system as described by Yamada et al. (1999). The number of defects any­where in the field are counted, and a weight factor for the severity of the defect is added: moderate defects are multiplied by two, severe defects by three. 8 (9) Horn et al. (2002) used the system as described by Yamada et al. in the C20-5 screening mode. 17 (10) The scoring system as described by Patel et al. (2000) in which defects in the central point are given a weight factor of 5, the four points surrounding the central point are given a weight factor of 3; furthermore, moderate defects are multiplied by 2 and severe defects by 3.5 (11) The simplified scoring system as described by Patel et al. (2000). A visual field is abnormal when any defect is present in the central 5 locations, at least 2 mild defects in the peripheral 12 test locations, or 1 moderate defect in the peripheral 12 test locations.5 (12) The scoring system as described by Iwasaki and Sugita (2002).18 An abnormal result is defined as one or more moderate or severe defects anywhere in the field, or two or more mild defects anywhere in the field, or at least one mild defect located within the four locations at the nasal side adjacent to the equator. (13) The scoring system as described by the American Academy of Ophthalmology (Delgado et al., 2002). 19 (14) Mean deviation (dB). (15) Pattern standard deviation (dB). The first five algorithms were examined for all possible severity levels. The algorithms (6) and (7) were evaluated at the severity level as mentioned above. Some algorithms were origi­nally applied in the screening mode of PDT. We converted our measurements obtained with the threshold mode to screening mode as described in Table 1, and subsequently calcu­lated the algorithm scores. Patel et al. have shown that test duration is a useful parameter in screening mode.5 Due to the design of the screening mode, test duration is directly propor­tional to the number of defects. In full-threshold mode, however, test duration is not related to the amount of damage. Therefore, we did not include this parameter in our analyses. In algorithms where the cut-off point could be varied, Areas Under the receiver-operating characteristic (ROC) Curve (AUC) were calculated using SPSS 10.0.7 (SPSS Inc., Chicago, IL, USA). In algorithms with a fixed cut-off point, sensitivities and specificities were cal­culated. With our sample size, an AUC of 0.90 has 95% confidence limits that range from 0.88 to 0.92. The limits of a sensitivity of 0.90 range from 0.87 to 0.93 and that of a spe­cificity of 0.80 from 0.75 to 0.85.20 All algorithms were evaluated in both the total and the pattern deviation plot. An Evaluation of Algorithms Designed to Classify the Results from FDT 67 
Table 1 Full-threshold equivalents of different levels of defect severity in screening mode. Full threshold 
P <  5% 
P < 2% 
P <  1% 






Screening C20 -1 
Mild 
Moderate 
Severe Table 2 Area under the receiver-operating characteristic curve (AUC) of frequency doubling perimetry algorithms in which the cut-off point could be varied; results for all glaucoma patients and normal subjects (a) and after the exclusion of patients with moderate and severe glaucoma (e). Algorithm 
Number of defects P < 0.5% anywhere 
Number of defects P < 1% anywhere 
Number of defects P < 2% anywhere 
Number of defects P < 5% anywhere 
Number of non-central defects P < 0.5% 
Number of non-central defects P < 1 % 
Number of non-central defects P < 2% 
Number of non-central defects P < 5% 
Number of defects in superior hemifield P < 0.5% 
Number of defects in superior hemifield P < 1 % 
Number of defects in superior hemifield P < 2% 
Number of defects in superior hemifield P < 5% 
Number of defects in inferior hemifield P < 0.5% 
Number of defects in inferior hemifield P < I% 
Number of defects in inferior hemifield P < 2% 
Number of defects in inferior hemifield P < 5% 
Scoring system by Patel et al. 
Scoring system by Yamada et al. 
Scoring system by Horn et al. 
Mean deviation (dB) 
Pattern standard deviation (dB) 68 Chapter 3 AUC (a) 0.91 0.92 0.92 0.92 0.91 0.92 0.92 0.92 0.88 0.90 0.90 0.90 0.86 0.89 0.89 0.90 0.92 0.92 0.92 0.91 0.87 AUC (e) 0.71 0.76 0.76 0.77 0.71 0.76 0.77 0.77 0.67 0.72 0.72 0.74 0.63 0.70 0.70 0.70 0.77 0.76 0.78 0.73 0.81 
Results Every algorithm was tested in both the pattern deviation and the total deviation plot. Mean area under the curve of all algorithms in the total deviation plot was 0.91 (SD 0.02), mean AUC in the pattern deviation plot was 0.84 (SD 0.06). In all algorithms the AUC was greater in the total deviation plot than in the pattern deviation plot. The same trend was seen in the sensitivity and the specificity of the algorithms with a fixed cut-off point. Therefore, we confined our further analyses to the results from the total deviation plot. The first column of Table 2 shows the area under the ROC curve for all algorithms where the cut-off point could be varied. AUCs ranged from 0.86 to 0.92. Simply counting the number of defects P < l % in the total deviation plot had an AUC of 0.92. Figure 1 presents the ROC curve of this algorithm. 
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1 - specificity As mentioned in the Methods section, it is not possible to calculate an area under the curve in algorithms with a fixed cut-off point. For these algorithms, we calculated sensitivity and specificity values. The first and the third column of Table 3 show the results. Simply counting the number of defects P < l % in the total deviation plot yielded a sensitivity of 0.90 and a specificity of 0.81 at a cut-off point of more than one defect. An Evaluation of Algorithms Designed to Classify the Results from FDT 69 
Table 3 Sensitivity and specificity of frequency doubling perimetry algorithms with a fixed cut-off point; results for all glaucoma patients(a) and after the exclusion of patients with moderate and severe glaucoma(e). Algorithm Sensitivity (a) Sensitivity (e) Specificity Two adjacent defects P < 0.5% anywhere 0.81 0.41 0.92 Two adjacent defects P < 1% anywhere 0.89 0.62 0.84 Two adjacent defects P < 2% anywhere 0.89 0.65 0.83 Two adjacent defects P < 5% anywhere 0.93 0.78 0.68 Two adjacent non-central defects P < 1% one hemifield 0.88 0.63 0.84 Scoring system by Burnstein et al. 0.86 0.52 0.85 Modified scoring system by Patel et al. 0.89 0.62 0.82 Scoring system by Iwasaki et al. 0.96 0.84 0.57 Scoring system by the American Academy of 0.93 0.80 0.67 Ophthalmology One reason for the apparently similar performance of the algorithms might be the fact that our group of glaucoma patients is rather heterogeneous, and thus also includes many patients with advanced disease. For that reason we repeated the analyses after the exclu­sion of patients with moderate and severe glaucoma, defined as MD(HFA) < -6 dB in the worse eye (i.e. more negative than -6 dB; patients with -6 dB or better are considered early glaucoma cases). The second column of Tables 2 and 3 show the results. Simply counting the number of defects P < I% in the total deviation plot now yielded an AUC of 0.76 and a sensitivity of 0.63. 70 Chapter 3 
Discussion In this study, we compared all previously published algorithms for the interpretation of PDT test results in a large group of glaucoma patients and normal subjects. Most of the algorithms appear to perform surprisingly similarly in terms of sensitivity, specificity, and area under the ROC curve. None of the algorithms seems to perform substantially better than the oldest algorithm as published by Quigley.3 For this algorithm, i.e. the number of defects P < I% in the total deviation plot, our analyses show a sensitivity of 0.90 and a spe­cificity of 0.81 at a cut-off point of > 1 defect, and an area under the curve of 0.92. Direct comparison of the originally published sensitivity and specificity values from dif­ferent studies is difficult because of methodological differences. A few studies compared two or more algorithms in the same group of patients. Their results are in agreement with our findings. Yamada et al. compared two algorithms. They did not find a difference in diagnostic performance. 8 Trible et al. found that sensitivity and specificity did not deviate more than 0.04 between the algorithms they tested. 6 Thomas et al. compared their newly developed algorithm to that of Quigley and Patel et al. 3•5•7 They did not find significant differences either. For an optimal methodological approach, all algorithms should be com­pared in one and the same dataset. Therefore, our study enables a better comparison of the various algorithms. The limited number of cut-off points available in the algorithms might imply that the per­formance of the algorithms could differ substantially in terms of sensitivity and specificity despite similar AUC values. However, this appeared not to be the case. For most of the algorithms, it was possible to find both a cut-off point yielding a sensitivity close to 0.90 and a cut-off point yielding a specificity close to 0.90. This is illustrated in Table 4. In this study we employed the PDT in full-threshold mode, which takes about 5 min per eye. Screening mode reduces test time to typically 1 min per eye by reducing the number of contrast levels presented to the patient. The screening mode, however, only produces a total deviation plot. As best results for all algorithms were obtained in the total deviation plot, it might be possible to screen patients using the faster screening mode without loss of diagnostic performance. The application of screening mode instead of full-threshold mode, however, could influence the performance of an algorithm. In an accompanying study we explored the differences between screening mode and full-threshold mode. 21  In conclusion, none of the algorithms performs substantially better than simply counting the number of defects P < I% in the total deviation plot. Because there is no significant dif­ference between this and other algorithms, we recommend using this algorithm. An Evaluation of Algorithms Designed to Classify the Results from FDT 7 1  
Table 4 Two possible sensitivity and specificity combinations of frequency doubling perimetry algorithms in which the cut-off point could be varied. a Algorithm Cut-off Sensitivity Specificity Cut-off Sensitivity Specificity Defects P < 0.5% anywhere >0 0.87 0 .83 >1 0.82 0.91 Defects P < 1 % anywhere >1 0.90 0 .81  >3 0.82 0.88 Defects P < 2 % anywhere >1 0.90 0 .80 >4 0.77 0.92 Defects P < 5% anywhere >2 0.91 0.72 >6 0.80 0.90 Non-central defects P < 0.5% >0 0.87 0.83 >1 0.82 0.92 Non-central defects P < 1% >1 0.90 0.81  >3 0.82 0.88 Non-central defects P < 2% >1 0.90 0 .80 >3 0.82 0.87 Non-central defects P < 5% >2 0.91 0.73 >6 0.79 0.90 Defects in superior hemifield P < 0.5% >0 0.80 0 .88 >0 0 .80 0.88 Defects in superior hemifield P < l % >0 0.88 0.78 >2 0 .75 0.92 Defects in superior hemifield P < 2% >0 0.89 0.77 >2 0.76 0.90 Defects in superior hemifield P < 5% >1 0.88 0.75 >3 0.78 0.88 Defects in inferior hemifield P < 0.5% >0 0.77 0.89 >0 0.77 0.89 Defects in inferior hemifield P < I% >0 0.87 0 .81  >2 0.74 0.91 Defects in inferior hemifield P < 2% >0 0.87 0 .81  >2 0.74 0.90 Defects in inferior hemifield P < 5% >0 0.92 0.59 >3 0.79 0.90 Scoring system by Patel et al. >1 0.90 0.78 >7 0.81 0.91 Scoring system by Yamada et al. >1 0.90 0.79 >5 0 .81  0.90 Scoring system by Horn et al. >6 0.90 0 .81  >12 0 .82 0.89 Mean deviation (dB) <-2 0.89 0.72 <-4 0 .80 0.88 Pattern standard deviation (dB) >5 0.90 0.70 >7 0.68 0.90 
a. In the first combination, sensitivity was made as close as possible to 0.90; in the second combination, specificity 
was made as close as possible to 0 .90. 72 Chapter 3 
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Abstract Purpose: To investigate the influence of inadequate anterior segment compensation on the screening performance of the nerve fiber analyzer with fixed anterior segment compensa­tion (GDx). Methods: GDx-parameter Ellipse Average was measured in the macula as a measure of the inadequacy of anterior segment compensation in 29 false-negative glaucoma cases (i.e., glaucoma patients with a normal GDx test result, defined as the Number <30) and 105 controls. The better the compensation, the lower the Ellipse Average. Results: Macula Ellipse Average was 57 ± 11 µm (mean ± SD) in the false-negative glau­coma cases and 62 ± 13 µm in the controls (P = 0.06). Conclusions: Inadequate anterior segment compensation does not seem to be the major cause of false-negative GDx test results. In fact, the false-negative glaucoma cases tended to have a more adequate anterior segment compensation then the controls. Inadequate Anterior Segment Compensation is Not a Major Cause of False-negative GDx 77 
Introduction The Nerve Fiber Analyzer (GDx) provides an in vivo assessment of the thickness of the nerve fiber layer by performing a peripapillary measurement of the retardation of polarized light.1 Differences that have been identified in the retinal thickness of glaucoma patients and normals, make the GDx a useful tool for the diagnosis and possibly the follow-up of glaucoma patients.1-5 The nerve fiber layer is not the only structure in the eye causing retardation. To adjust for polarization induced by cornea and lens, anterior segment compensation was incorporated into the design of the GDx. In all but the latest release of the GDx, this compensation was fixed and assumed a corneal polarization direction of 15 degrees nasally downward and a magnitude of 60 nm. This fixed compensator has been shown to be adequate in only 30% of the population, due to inter-individual variation in corneal birefringence. 6 The adequacy of the fixed compensation can be estimated by making a GDx scan of the macula. Retardation in the macula is caused by the birefringence property of the Henle fibers, which are radially oriented around the fovea and give rise to a uniform pattern of small retardation and any modulation of retardation in the macula is caused by inad­equate anterior segment compensation. Therefore an inadequacy of compensation results in the measurement of more retardation in the macula (Garway-Heath DF, ARVO Meeting, 2000, Abstract).6 This principle has been used in a more recent version of the GDx, the GDx-VCC. Increased retardation due to inaccurate anterior segment compensation might be masking axonal loss in glaucoma. Therefore, the aim of the present study was to investigate whether the adequacy of anterior segment compensation, as assessed through a quantitative measure of the retardation of the macula, differs between misclassified glaucoma patients (i.e., false negative cases) and controls. 78 Chapter 4 
Methods The dataset has been described before.7 In short, 452 glaucoma patients from our hospital who agreed to participate (informed consent) were included for an (IRB approved) prospec­tive follow-up with GDx (Version 2.0.10; Laser Diagnostic Technologies, San Diego, CA). A glaucoma patient was defined as a patient with a reproducible defect on conventional perimetry in at least one eye. Defects had to be compatible with glaucoma and without any other explanation. In addition, 237 healthy subjects were recruited outside the hos­pital.7 At baseline, a GDx scan of the peripapillary region was performed, which was then used to classify the glaucoma patients as either true-positive (n=406; sensitivity = 0.90) or false-negative (n=46). At a later occasion, a GDx scan of the macula was performed in a random subset of 29 (out of 46) false-negative glaucoma patients (cases) and 105 (out of 237) healthy subjects (controls). An experienced operator performed scanning laser polarimetry in a standardized fashion. A series of six peripapillary scans with a concentric measurement ellipse of 1. 75 times the disk diameter, centered on the optic disk were made. Scan quality was deemed high when the scan met the following criteria: a centered optic disc well focused image, even illumina­tion throughout the image, and the absence of motion artifacts. One to three high quality images from each series were used for analysis. 8 An abnormal GDx test was defined as GDx-parameter the Number >29 in at least one eye.7 In case of only one functional eye, only that eye was used for classifying the patient and determining the test result. The adequacy of the anterior segment compensation was esti­mated from a GDx scan of the macula using GDx-parameter Ellipse Average. This macula scan was performed on the cases in the eye with the most perimetric glaucomatous damage and in the right eye of the controls.7 For the macular scan, an ellipse of 800 µm was centered around the foveal vascular zone. Scan quality was judged according to the aforementioned criteria. One to three high quality images from each series were used for analysis. Macula Ellipse Average values of the cases (false-negative glaucoma patients) were com­pared to those of the controls using a t-test. Inadequate Anterior Segment Compensation is Not a Major Cause of False-negative GDx 79 
Results Figure 1 shows that GDx-parameter Ellipse Average increases monotonically with the amount of retardation in the macula, indicating that it is a useful measure of the inad­equacy of anterior segment compensation. Macula Ellipse Average was 57 ± 11 µm (mean ± SD) in the false-negative glaucoma patients and 62 ± 13 µm in the controls. This difference is not significant (P = 0.06). In fact, the cases tended to be better compensated than the controls (one-sided t-test P = 0.97). FIGURE I .  Examples of macula scans showing good (A), borderline (B), and inadequate (C) anterior segment compensa­tion, classified according to previously published criteria. 2 In our cases and controls, GDx-parameter Ellipse Average showed a monotonic increase with increasing inadequacy of compensation: 48 ± 6 µm (mean ± SD) in scans classified as good compensation (n=30), 59 ± 7 µm in scans classified as borderline compensation (n=72), and 78 ± 9 µm in scans classified as inadequate compensation (n=32). A (N=30) 
Good Compensation 80 Chapter 4 B (N=72) C (N=32) Borderline Compensation Inadequate Compensation 
Discussion Suboptimal anterior segment compensation results in a macula Ellipse Average of typically 60 µm. This value is non-negligible when compared to the peripapillary Ellipse Average: 79 ± 17 µm in our healthy subjects. Thus, it can tentatively be concluded that neural net­work GDx-parameter the Number is -to some extent- able to discriminate between retar­dation due to inadequate anterior segment compensation and retardation due to the nerve fiber layer. The explanation for the lack of effect of inadequate corneal compensation on the results of the GDx is most likely that the Number, traditionally the best parameter for judging peripapillary GDx scans, is the output parameter of a neural network that uses all avail­able information rather than only the amount of retardation. As shown in Figure I, an inadequate corneal compensation increases the amount of retardation in the macular scan almost linearly. In the result of the peripapillary scan this anterior segment retardation is added to the retardation of the nerve fiber layer in the peripapillary region. Therefore if the number would take only the amount of retardation into account it would be severely affected by inadequate corneal compensation. However the Number also takes the shape of the retardation image (the modulation) into account. The influence of inadequate corneal compensation on the modulation of the retardation image is a lot less severe, as is shown in Figure 1. 6 Figure IA shows hardly any modulation (an even blue scan) in the macula scan of a patient with an adequately compensated cornea. When corneal compensation is slightly inadequate the modulation of the retardation image increases (Figure IB). When corneal compensation is grossly abnormal (Figure IC) modulation decreases again. Thus inadequate corneal compensation changes the modulation of the retardation image only minimally. In agreement with our finding, studies using individualized anterior segment compensa­tion failed to find a substantial increase in screening performance of GDx-parameter the Number.9•10 A study using a more recent GDx release (GDx-VCC, a GDx with variable corneal compensation), however, showed some increase in screening performance.11 A decrease in measurement time and an increased ease of use may at least partially explain the difference. In conclusion, in this dataset, inadequate anterior segment compensation does not seem to be the major cause of false-negative GDx nerve fiber analyzer test results. Inadequate Anterior Segment Compensation is Not a Major Cause of False-negative GDx 81 
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Abstract Purpose: To determine the association between systemic antihypertensive medication and incident open-angle glaucoma. Design: Prospective population-based cohort study. Participants: The study population consisted of a subset of 3842 part1c1pants of the Rotterdam Study for whom data from identical ophthalmologic examinations at baseline and follow-up were available. Methods: Use of antihypertensive medication was registered over an average follow-up period of 6.5 years. Associations between incident open-angle glaucoma and antihyperten­sive medication were assessed using multivariate logistic regression models adjusted for age, gender, duration of follow-up, intraocular pressure, intraocular pressure-lowering medica­tion, and cardiovascular disease. Main Outcome Measures: Odds ratios of associations between incident open-angle glau­coma and use of antihypertensive medication. Results: During follow-up, there were 87 incident cases of open-angle glaucoma. Partici­pants using calcium channel antagonists had a 1.8-fold (95% confidence interval [CI], I.04-3.2; P = 0.037) higher risk of developing incident open-angle glaucoma. Beta-block­ers were associated with a nonsignificant risk reduction (odds ratio, 0.6; 95% CI, 0.3-1.02; 
P = 0.060). None of the other classes of antihypertensives was significantly associated with incident open-angle glaucoma. Conclusions: These data suggest that use of calcium channel antagonists is associated with open-angle glaucoma, but this requires confirmation. These results do not support the use of calcium channel antagonists for the treatment of normal-tension glaucoma. Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 85 
Introduction Open-angle glaucoma (OAG) is a chronic progressive optic neuropathy with elevated intraocular pressure (IOP) as its main risk factor. The incidence and progression of OAG are correlated with the IOP, and a reduction in IOP in turn reduces both the incidence and progression of OAG .1-3 Other established risk factors for OAG are a positive family history of OAG,4-6 age, and myopia. 1 •7-12 Besides the established risk factors, there is an ongoing debate in the literature concerning the effect of hemodynamic changes on the optic nerve perfusion and, therefore, on the incidence of OAG. For instance, a number of studies have suggested hypertension to be a risk factor for OAG. 13-16 Because hypertension generally is treated with antihypertensive medication, often it is difficult to distinguish whether an increased risk of OAG results from hypertension or from its treatment. For instance, beta-blockers, which are commonly used as antihypertensives, induce a vasoconstriction of peripheral vessels and may cause hypo-perfusion of the optic nerve. 17 Calcium channel antagonists are peripheral vasodila­tors and therefore may increase optic nerve perfusion, which in turn may protect against OAG. 18• 19 Other groups of antihypertensives have different mechanisms of action and may alter the blood flow to the optic nerve in other ways. Because these theories largely are based on research in animals, little is known about the effects of antihypertensives in humans. This study examined the association between the use of antihypertensive medication and incident OAG (iOAG) in a subset of the prospective population-based Rotterdam Study. 20 86 Chapter 5 
Patients and Methods 
Study Population The study population consisted of participants in the Rotterdam Study. The Rotterdam Study is a prospective population-based cohort study of individuals aged 55 years and older living in the Ommoord district of Rotterdam. The rationale and study design have been described previously.20 Of the original eligible cohort of 10 275 individuals, 7983 persons (78%) participated in the study. For the present study, a subset of 3842 participants was used for whom ophthalmologic examination data at baseline and follow-up were avail­able. 8 Mean follow-up time was 6.5 years (range, 5.0-9.4 years). All measurements were conducted after the Medical Ethics Committee of the Erasmus University had approved the study protocol and all participants had given a written informed consent in accordance with the Declaration of Helsinki. Baseline examinations took place from 1990 through 1993; follow-up examinations were performed from 1997 through 1999. 
Open-angle Glaucoma At baseline and follow-up, identical ophthalmic examinations were performed that con­sisted of Goldmann applanation tonometry, visual field screening and ophthalmoscopy, and stereoscopic fundus photography with pharmacologic mydriasis. 8 Open-angle glaucoma was diagnosed using previously published criteria. 8•21 Briefly, an algorithm was used for the diagnosis of OAG based on presence or absence of glaucomatous optic neuropathy (GON), glaucomatous visual field loss, or both, yielding a classification as no, possible, probable, or definite OAG. To be eligible for a diagnosis of OAG, participants were required to have an open anterior chamber angle and no history or signs of angle closure or secondary OAG. Incident OAG was defined as no or possible OAG in both eyes at baseline and probable or definite OAG in at least 1 eye at follow-up. Excluded from this incidence definition were persons with possible GON at baseline and probable GON at follow-up as the only change because of variability in measuring GON and because a tiny increase in one of the GON criteria could lead to a change in this classification. 8 
Medication Data Data on antihypertensive medication prescription were obtained from the 7 pharmacies in the Ommoord region. These pharmacies are fully automated and use 1 computer network to register all prescriptions of drugs used from January 1, 1991, onward. Antihypertensives were categorized into 6 classes based on their pharmacologic working principle. These classes were: low-ceiling diuretics, high-ceiling diuretics, beta-blockers, calcium channel antagonists, ACE-inhibitors, and angiotensin II antagonists. For each class of antihyper­tensives, data on duration and daily drug dosage of the medication were available. Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 87 
Cardiovascular Data For each participant, data on cardiovascular disorders (i.e., hypertension, heart failure, atrial fibrillation, myocardial infarction, angina pectoris, stroke, and diabetes mellitus) were recorded. 22-28 Cardiovascular data were obtained through interviews of the partici­pants, electrocardiogram readings, and nonfasting and fasting serum blood glucose levels at baseline and during follow-up. Cardiovascular events between baseline and follow-up were recorded via continuous monitoring through automated linkage with files from gen­eral practitioner information systems. Hypertension was defined as use of antihypertensive medication for the indication of hypertension or as a systolic blood pressure of 140 mmHg or more, or a diastolic pressure of 90 mmHg or more.22 Mean arterial pressure was defined as (systolic pressure+2xdiastolic pressure)/3. 
Data Analyses Differences in characteristics between participants with and without incident OAG were evaluated with the chi-square test for dichotomous variables and the t-test or Mann­Whitney U test for continuous variables. Associations between iOAG and antihypertensive medication were assessed using logistic regression models, adjusted for age (at follow-up), gender, duration of follow-up, IOP (for each eye the median of 3 Goldmann tonometer measurements at baseline was recorded; the highest IOP of both eyes was used), and IOP treatment (i.e., use of !OP-lowering drugs at baseline) to calculate odds ratios with 95% confidence intervals (95% Cls). The null hypothesis was that there would be no associa­tion between antihypertensive medication and iOAG. In case of a significant association between a medication class and iOAG, dose-response relationships were evaluated with trend tests. Possible confounding by the presence of hypertension and other cardiovascular diseases, hypertension regulation (using mean arterial pressure as a proxy), and the severity of cardiovascular disease also were examined. Effect modifications were investigated with interaction terms. All statistical analyses were performed using SPSS software for Windows version 12.0.1 (SPSS Inc., Chicago, IL). A P  value < 0.05 was considered to be statistically significant. 88  Chapter 5 
Results During follow-up, iOAG developed in 87 participants. Table 1 presents the characteristics of the study population. Participants with iOAG on average were older and had a higher IOP at baseline. There were no differences between groups regarding the presence of car­diovascular disorders. Table 2 shows the results of univariate analyses for the use of medica­tion at any time during follow-up. These analyses were suggestive of more frequent use of calcium channel antagonists amongst participants with iOAG (21 of 87 [24.1%]) than in participants without iOAG (614 of 3755 [16.4%]), but the association was not significant 
(P = 0.055). No other differences between use of medication in both groups of participants were noted. Table 3 presents the results of multivariate logistic regression analysis of all classes of medi­cation, adjusted for age, gender, duration of follow-up, IOP, and use ofIOP-lowering drugs. In this analysis, the risk of developing iOAG was 1.9-fold higher in participants taking calcium channel antagonists (95% CI, 1.1-3.3; P = 0.034). Patients taking beta-blockers apparently had a lower risk of developing iOAG, but this was not significant (odds ratio, 0.6; 95% CI, 0.4 -1.1; P = 0.124). Table 4 shows the results of multivariate logistic regression analysis of beta-blockers and calcium channel antagonists adjusted for cardiovascular diseases, age, gender, duration of follow-up, IOP, and use ofIOP-lowering drugs. The addition of cardiovascular diseases did not substantially influence the outcome of the analysis, and no significant effects of cardio­vascular disease on iOAG were found, except for an apparent protective effect of diabetes mellitus. Table 5 presents the final model, adjusting for age, gender, duration of follow-up, IOP, and use of !OP-lowering drugs, that served as a starting point for the additional analyses as presented herein. Participants using calcium channel antagonists had a 1.8-fold (95% CI, 1.04-3.2; P = 0.037) higher risk of experiencing iOAG. beta-Blockers were associated with a nonsignificant risk reduction (odds ratio, 0.6; 95% CI, 0.3-1.02; P = 0.060). A dose-effect relation for beta-blockers and calcium channel antagonists was explored by stratification of medication use in O, 1 to 365, and >365 days. Figure 1 shows the results. A trend analysis with calcium channel antagonists and beta-blockers implemented as ordinal variables (0-2: 0, no use; 1, 1-365 days of use; 2, >365 days) in the model as displayed in Table 5 showed a significant trend for both calcium channel antagonists (P = 0.015) and beta-blockers (P = 0.036). Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 89 
Table 1 Characteristics of Participants with and without Incident Open-angle Glaucoma (OAG). No incident OAG Incident OAG P value (n=3755) (n=87) Sex (% female) 58 53 0.38 Median age (yrs) (SD) 71.2(6.9) 74.2(7.1) <0.001 Median IOP (mmHg) (SD) 16.1(3.1) 17. 1 (4.0) <0.001 I OP-lowering drugs (%) 1 .5 1 1 .5 <0.001 Hypertension(%) 61 . 1  67.8 0.222 Myocardial Infarction (%) 4.1 4.6 0.782 Angina Pectoris (%) 27.4 33.3 0.226 Heart Failure (%) 6.7 6.9 0.829 Stroke (%) 4.3 4.6 0.788 Diabetes Mellitus (%) 1 1 .8 6.9 0 .137 IOP = Intraocular pressure; SD = Standard Deviation. Intraocular pressure was determined at baseline, age and cardiovascular risk factors were determined at follow-up. Table 2 Univariate Analyses of Use of Medication (for Each Medication Class) at Any Time during Follow-up and the Development of Incident Open-angle Glaucoma (iOAG). Low-ceiling diuretics (%) High-ceiling diuretics (%) Beta-blockers (%) Calcium channel antagonists (%) ACE-inhibitors (%) ACE = angiotensin-converting enzyme. 90 Chapter 5 Incident No incident OAG OAG 20.7 23.9 10.3 10.8 25.3 30.8 24.1 16.4 18 .4 17.9 95% Confidence Odds Ratio Interval 0.8 0.5 - 1 .4 0.9 0.5 - 1 .9 0.8 0.5 - 1.2 1 .6 1.0 - 2.7 1 .0 0.6 - 1.8 P value 0.486 0.883 0.269 0.055 0.916 
Table 3 Multivariate Analysis of Risk of Developing Incident Open-angle Glaucoma for All Classes of Medication Adjusted for Age, Gender, Duration of Follow-up, lntraocular Pressure (IOP), and Use oflntraocular Pressure-Lowering Drugs. 95% Confidence Odds Ratio Interval P value Low-ceiling diuretics 0.8 0.4 - 1 .4 0.430 High-ceiling diuretics 0.8 0.4 - 1 .8 0.659 Beta-blockers 0.6 0.4 - 1 . 1  0 . 124 Calcium channel antagonists 1 .9 1 . 1  - 3.3 0.034 ACE-inhibitors 0.9 0.5 - 1 .7 0.747 Follow-up (per day) 1 .00 0.99 - 1 .00 0. 1 33 Sex 0.9 0.5 - 1.3 0.492 Age {per year) 1 .06 1 .02 - 1 .09 0.001 IOP (per mmHg) 1 .14 1 .08 - 1 .21 <0.001 IOP lowering drugs 4.6 2.1 - IO.I <0.001 ACE = angiotensin-converting enzyme. Table 4 Multivariate Logistic Regression Analysis of Beta-Blockers and Calcium Channel Antagonists Adjusted for Cardiovascular Diseases, Age, Gender, Duration of Follow-up, lntraocular Pressure (IOP), and Use of lntraocular Pressure-Lowering Drugs. 95% Confidence Odds Ratio Interval P value Beta-blockers 0.6 0.3 - 1 .0 0.056 Calcium channel antagonists 1 .7 1 .0 - 3. 1  0.061 Follow-up (per day) 1 .00 0.99 - 1 .00 0 . 121  Sex 0.8 0.5 - 1 .3 0.410 Age {per year) 1 .06 1 .02 - 1 .09 0.001 Atrial fibrillation 0.6 0.1 - 5.2 0.663 Myocardial infarction 1.0 0.4 - 3.0 0 .958 Angina pectoris 1.3 0.8 - 2.1 0.289 Heart failure 0.8 0.3 - 2.0 0.624 Hypertension 1 .2 0.7 - 1 .9 0.506 Stroke 0.9 0.3 - 2.7 0.898 Diabetes mellitus 0.4 0.2 - 1.0 0.044 IOP (per mmHg) 1 . 14 1 .08 - 1 .21 <0.001 IOP lowering drugs 5.1 2 .3 - 1 1 .3 <0.001 Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 9 1  
Table 5 Multivariate Analysis of Risk of Developing Incident Open-angle Glaucoma for Beta-blockers and Calcium Channel Antagonists Adjusted for Age, Gender, Duration of Follow-up, lntraocular Pressure {IOP), and Use of lntraocular Pressure Lowering Drugs. 95% Confidence Odds Ratio Interval Pvalue Beta-blockers 0.6 0.34 - 1 .02 0.060 Calcium channel antagonists 1 .8 1 .04 - 3. 19 0.037 Follow-up (per day) 1 .00 1 .00 - 1.00 0.125 Sex 0.9 0.5 - 1 .3 0.476 Age (per year) 1 . 1  1 .02 - 1 .08 0.001 IOP (per mmHg) 1 . 1  1 . 1  - 1 .2 <0.001 IOP lowering drugs 4.8 2.2 - 10.4 <0.001 
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0 0-365 >365 Duration of medication use (days) □ Beta-blockers ■ Calcium channel antagonist The influence of hypertension regulation was studied by adding mean arterial pressure to the model of Table 5. This had no influence {calcium channel antagonists, P = 0.04; beta­blockers, P = 0.06; mean arterial pressure, P = 0.89). An index for the severity of hyper­tension during follow-up was obtained by calculating the number of simultaneously used antihypertensives. Adding this variable to the model as displayed in Table 5 did not yield any substantial effect, suggesting that confounding by severity of hypertension did not play a major role. An interaction analysis with IOP showed no significant effect for either beta-blockers (P = 0.19) or calcium channel antagonists (P = 0.16). An interaction analysis for beta-blockers and calcium channel antagonists was not significant (P = 0.94). 92 Chapter 5 
Discussion Calcium channel antagonists were used more frequently by participants in whom iOAG developed, and beta-blockers seemed to be used less frequently by participants in whom iOAG developed, although this did not reach statistical significance. None of the other classes of antihypertensives showed a significant association with the development of iOAG. The presence of a dose-effect relation and the absence of demonstrable confounding by indication or confounding by severity further supports the validity of these findings. These results concerning calcium channel antagonists and beta-blockers are consistent with an earlier large-scale case-control study by Langman et al, 29 who found a significant risk increase of OAG in users of calcium channel antagonists. Also, their study was suggestive of a slight beneficial effect of oral beta-blockers. Furthermore, an earlier population-based study showed a reduced risk of OAG in people using antihypertensives, but this result was not statistically significant. 30 In that study, no attempt was made to distinguish between different classes of antihypertensives. Because beta-blockers are the most frequently pre­scribed class of antihypertensives ( Table 2), the results of their study3° are in line with the present results: the protective effect of antihypertensives may be attributed to the domi­nating effect of the beta-blockers. The present results seem to contradict several studies that advocate the use of calcium channel antagonists in normal-tension OAG patients. The bases of this recommendation are the results of several human and animal studies that have shown blockade of mem­brane-bound calcium channels to induce ocular vascular dilatation and to improve optic nerve perfusion.17•18•31 There are some reports showing visual field improvements of normal­tension OAG patients after using calcium channel antagonists.32 •33 Differences between these studies and the present results may be the result of patient selection in the aforemen­tioned studies, which could mean that there may be a small, selective group of normal­tension OAG patients who may benefit from calcium channel antagonists. However in the present study, no significant interaction between IOP and calcium channel antagonist use was found. Because results of earlier reports are by no means conclusive, and the present results suggest that calcium channel antagonists may have a harmful effect on develop­ment of OAG, the treatment of OAG patients with calcium channel antagonists should be handled with caution and in fact may be contraindicated. Because of its design, the present study cannot reveal the biological basis of its findings, but a possible explanation for this harmful effect may be that although calcium channel antagonists dilate ophthalmic and posterior ciliary vessels, blood pressure is decreased without decreasing IOP, thus reducing ocular perfusion pressure.34 Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 93 
Several reports indicate that nonselective beta-blockers in OAG therapy may lower optic nerve perfusion and thus increase glaucomatous damage to the optic nerve. Two prospec­tive studies reported that betaxolol, a selective beta-blocker, was significantly better at pre­serving the visual field when compared with a nonselective beta-blocker. 35•36 However, the statistical significance of this difference was lost after 24 to 48 months. In the current study, there was no increased risk of OAG in participants using beta-blockers. The relative risk actually was lower for participants using this class of medication, which was consistent with the results of the study by Langman et al. 29 An earlier study did not demonstrate beta-adrenergic receptors in optic nerve vessels. 37 Therefore, the hypothesis of an increased resistance in optic nerve perfusion caused by beta-blockers also seems unlikely on theo­retical grounds. For this reason, there is no current evidence for discontinuing beta-blocker therapy in persons with OAG. Differences in the regulation of hypertension by different antihypertensive regimens might have contributed to the associations as found in this study. However, this is unlikely to be the case because adding mean arterial pressure to the analyses had no influence. Several earlier population-based studies showed cardiovascular disease and diabetes mellitus as risk factors for the development of OAG. 3s-4o The current study did not show a significant effect of cardiovascular diseases or diabetes mellitus on the development of OAG. Differences between this study and the earlier population-based studies may be a result of differences in study design. The earlier studies were prevalence studies, whereas the current study is an inci­dence study. This difference is also shown in the present data. An association between dia­betes, hypertension, and OAG was shown in 2 prevalence papers from the Rotterdam Study; however, this association disappeared when incidence data were used. 1 3•16•28•4 1 Furthermore, the current results confirm several earlier population-based studies that showed no harmful effect of cardiovascular disorders and diabetes on OAG.1 • 14•42•43 The strength of the current study is its design: a prospective, population-based study of iOAG with a fully automated system of pharmacologic data collection. All pharmacies in the Ommoord region used 1 computer network to register all prescriptions. This resulted in a complete overview of each participant's medication use during the follow-up period. Although a potential limitation of this approach is that whether all participants took their medication is unknown, such exposure misclassification usually is similar in cases and controls and leads to conservative risk estimates. Another limitation of this study is the small number of cases with iOAG. This is the result of both the number of nonparticipants at follow-up and the stringent criteria used for the diagnosis of OAG in this study. 8 A large number of nonparticipants at follow-up was to be expected because this cohort was composed of elderly participants. Of all participants, 19% died during follow-up and 22% 94 Chapter 5 
declined follow-up examinations. Nevertheless, the participation rate at follow-up was quite high when compared with that of other population-based studies such as the Barbados and Melbourne eye studies. 44•45 In conclusion, there is no indication that we must alter treatment paradigms for systemic hypertension in glaucoma patients or glaucoma suspects, because the commonly used beta­blockers and diuretics do not seem to be harmful and the use of calcium channel antagonists is already limited to complicated cases of hypertension. Use of calcium channel antagonists or discontinuing beta-blockers in patients with normal-tension glaucoma cannot be recom­mended on the basis of the results of this study. Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 95  
References 1. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open­angle glaucoma: the Visual Impairment Project. Invest Ophthalmol Vis Sci 2003;44:3783 -9. 2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progres­sion: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79. 3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a ran­domized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13, discussion 829-30. 4. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma: popula­tion-based familial aggregation study. Arch Ophthalmol 1998;116: 1640-5. 5. Tielsch JM, Katz J, Sommer A, et al. Family history and risk of primary open angle glaucoma: the Baltimore Eye Survey. Arch Ophthalmol 1994;112:69-73. 6. Rosenthal AR, Perkins ES. Family studies in glaucoma. Br J Ophthalmol 1985;69:664-7. 7. Leske MC, Nemesure B, He Q, et al. Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology 2001;108:1015-22. 8. de Voogd S, lkram MK, Wolfs RC, et al. Incidence of open-angle glaucoma in a general elderly population. The Rotterdam Study. Ophthalmology 2005;112:1487-93. 9. Ramrattan RS, Wolfs RC, Panda-Jonas JB, et al. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. Arch Ophthalmol 2001;119:1788-94. 10. Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia . The Blue Mountains Eye Study. Ophthalmology 1999;106:2010-5. 11. Wong TY, Klein BE, Klein R, et al. Refractive errors, intraocular pressure, and glaucoma in a white population. Ophthalmology 2003;110:211-7. 12. Grodum K, Heijl A, Bengtsson B. Refractive error and glaucoma. Acta Ophthalmol Scand 2001;79:560-6. 13. Dielemans I, Vingerling JR, Algra D, et al. Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population: the Rotterdam Study. Ophthalmology 1995; 102:54-60. 14. Bonomi L, Marchini G, Marraffa M, et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000;107:1287-93. 15. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma: a population-based assessment. Arch Ophthalmol 1995;113:216-21. 16. Hulsman CA, Borger PH, Vingerling JR, et al. Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam Study. Arch Ophthalmol 2007;125:805-12. 17. Yu DY, Su EN, Cringle SJ, et al. Systemic and ocular vascular roles of the antiglaucoma agents b-adrenergic antagonists and Ca2(+) entry blockers. Surv Ophthalmol 1999;43(suppl):s214-22. 18. Takayama J, Tomidokoro A, Tamaki Y, Araie M. Time course of changes in optic nerve head circu­lation after acute reduction in intraocular pressure. Invest Ophthalmol Vis Sci 2005;46:1409-19. 96 Chapter 5 
19. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001 ;20:319-49. 20 . Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and dis­ability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22 . 21 . Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences - the Rotterdam Study. Invest Ophthalmol Vis Sci 2000;41:3309-21.  22. Ikram MK, Wineman JC, Vingerling JR, et al. Retinal vessel diameters and risk of hypertension: the Rotterdam Study. Hypertension 2006;47:189-94 . 23. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53. 24 . Bleumink GS, Knetsch Am, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure . The Rotterdam Study. Eur Heart J 2004;25: 1614-9. 25 . de Torbal A, Boersma E, Kors JA, et al . Incidence of recognized and unrecognized myo­cardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J 2006;27:729-36. 26. Hollander M, Bots ML, del Sol AI, et al . Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation 2002;105:2872-7. 27. Maitland-van der Zee AH, Klungel OH, Stricker BC, et al. Repeated nitrate prescriptions as a potential marker for angina pectoris: a comparison with medical information from the Rotterdam Study. Pharm World Sci 2003;25:70-2 . 28. de Voogd S, lkram MK, Wolfs RC, et al. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology 2006; 1 13: 1827-31 .  29. Langman MJ, Lancaster RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mecha­nisms in common and co-occurrence. Br J Ophthalmol 2005;89:960-3. 30 . Klein BE, Klein R, Knudtson MD. lntraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol 2005;89:284-7. 31 . Orgul S, Gugleta K, Flammer J .  Physiology of perfusion as it relates to the optic nerve head. Surv Ophthalmol 1999;43(suppl):sl7-26. 32. Kitazawa Y, Shirai H, Go FJ . The effect of Ca2(+) -antagonist on visual field in low-tension glau­coma. Graefes Arch Clin Exp Ophthalmol 1989;227:408-12. 33. Netland PA, Chatuverdi N, Dreyer EB. Calcium channel blockers in the management of low-ten­sion and open-angle glaucoma. Am J Ophthalmol 1993; 1 15:608-13. 34. Tamaki Y, Araie M, Tomita K, Tomidokoro A. Time-course of changes in nicardipine effects on microcirculation in retina and optic nerve head in living rabbit eyes. Jpn J Ophthalmol 1996;40:202-1 1. 35 . Messmer C, Flammer J ,  Stumpfig D. Influence ofbetaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 1991;1 12:678 -81 .  Systemic Antihypertensive Medication and Incident Open-angle Glaucoma 97 




Ophthalmology 2008; in press 
ROGIER P. H. M. MUSKENS, MD, 1 '2 ROGER C. W. WOLFS, MD, PHD, 2•3 
JACQUELINE C. M. WITTEMAN, PHD, 2 ALBERT HOFMAN, MD, PHD, 2 
PAULUS T. V. M. DE JONG, MD, PHD,2•4•5 BRUNO H. C. STRICKER, PHD,2 
NOMDO M. JANSONI US, MD, PHD1 '2 1 .  University Medical Center Groningen, University of  Groningen, Groningen, the Netherlands 2. Department of Epidemiology & Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands 3. Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands 4. Department of Ophthalmology, Academic Medical Center, Amsterdam, the Netherlands 5. The Netherlands Institute for Neurosciences, KNAW, Amsterdam, the Netherlands 

Abstract Purpose: To study the associations between long-term and short-term use of topical beta­blockers and mortality. Design: Prospective population-based cohort study. Participants: Long-term effects: 3842 participants aged 55 years and older. Short-term effects: 484 incident beta-blocker users and 4700 age-matched controls. All participants were recruited as part of the Rotterdam study. Methods: Long-term effects: Associations between topical beta-blocker use prior to and at baseline, between 1990 and 1997, and mortality between 1997 and 2005, were studied. Data were analyzed using Cox regression and hazard ratios were adjusted for age, sex, smoking, systemic hypertension, diabetes mellitus and angina pectoris. Short-term effects: These were defined as death within three months after the first prescription of a topical beta-blocker. Mortality was compared between incident beta-blocker users, that is, partici­pants who started using a topical beta-blocker between the onset of the Rotterdam study in 1990 and October 1, 2004, and age-matched controls. Short-term effects were examined using a chi-squared test. Confounding by smoking was analyzed by stratification. Main outcome measures: Long-term effects: Hazard ratios of topical beta-blocker use for all-cause mortality and cardiovascular mortality. Short-term effects: Chi-squared statistics between mortality of incident topical beta-blocker users and age-matched controls. Results: Long-term effects: Mean age at baseline was 72 years (Standard Deviation 7 years). Topical beta-blockers were used by 228 participants. 709 participants died during follow­up (18%); 135 (3.5%) had a cardiovascular cause of death. The hazard ratio of topical beta­blocker use was 0.94 (95% confidence interval 0.71-1.25; P = 0.69) for all-cause mortality and 1.02 (0.56-1.86; P = 0.95) for cardiovascular mortality. Short-term effects: four (0.8%) of the 484 incident topical beta-blocker users died within three months after their first prescription; 65 (1.4%; P = 0.31) of the 4700 aged-matched controls died within a similar period. Conclusions: Use of topical beta-blockers appears not to be associated with mortality. Topical Beta-blockers and Mortality 101 
Introduction Topical beta-blockers have served as first-line drugs for the treatment of glaucoma for the past three decades. During this period several conflicting reports have been published con­cerning an association between the use of topical beta-blockers and mortality. Two major prospective multicenter randomized controlled studies on the treatment of glaucoma, the Early Manifest Glaucoma Trial (EMGT) and The Ocular Hypertension Treatment Study (OHTS), investigated whether an association between treatment of glau­coma and mortality was present.1 •2 A non-significant trend for decreased survival among patients treated with betaxolol, compared with those receiving no treatment, was reported by the EMGT. The OHTS did not find a reduction in survival among ocular hypertensive patients receiving pressure-lowering medication (3.2%), when compared with those under observation (3.5%), either. Recently, however, an association between the use of topical timolol and cardiovascular mortality was reported in the Blue Mountains Eye Study.3 The result of this latter report seems to contradict a large number of publications concerning systemic beta-blockers and their benefits in cardiovascular disease. Ever since the beneficial effects of beta-blockers on cardiovascular disease were shown in the Myocardial Infarction trials in the early 1980s, they have been reproduced in many other trials concerning dif­ferent cardiovascular disorders.4•5•6 Because of the results of these trials, beta-blockers have become a mainstay in the therapy for cardiovascular disorders. For this reason, the associa­tion between the use of a topical beta-blocker and an increase in cardiovascular mortality would seem counterintuitive. One possible adverse effect on cardiovascular disease from topical beta-blockers could come from the adverse effect that timolol, in particular, has on the serum lipid spectrum. Timolol is known to increase the ratio of Low-Density Lipoprotein (LDL) to High-Density Lipoprotein. An increased LDL fraction will yield a higher risk of coronary events.7 The aim of this study was to investigate the effects of topical beta-blockers on mortality in three ways. First, we investigated the long-term effects on mortality of the use of topical beta­blockers; the aim of this part of our study was to repeat the analyses of the Blue Mountains Eye Study in our own study. Second, and related to the first part, the authors went on to investigate whether there indeed was an effect from the use of topical beta-blockers on the serum lipid spectrum. Third, we investigated the short-term effects of topical beta-blockers on mortality (that is, death shortly after the first prescription). 102 Chapter 6 
Methods 
Study Population The present study was performed within the Rotterdam Study, a prospective population­based cohort study of all residents aged 55 years and older living in the Ommoord suburb of Rotterdam. The rationale and study design have been described elsewhere. 8 All measurements were conducted after the Medical Ethics Committee of the Erasmus University had approved the study protocol and all participants had given a written informed consent in accordance with the Declaration of Helsinki. Participant inclusion took place from 1990 through 1993. For the long-term analyses in our present study, data from a follow-up examination per­formed between 1997 and 1999 were used to define a secondary baseline. This approach enabled us to examine the effects of long-term use of topical beta-blockers prior to the sec­ondary baseline. For this part of the study, data from 3842 participants were available. The analyses of the influence of topical beta-blockers on cholesterol were also performed using these 3842 participants. For our analyses of the short-term effects of topical beta-blockers, 484 incident topical beta-blocker users, that is, participants who had started using a topical beta-blocker after the onset of the Rotterdam study in 1990, were compared to an age­matched group of 4700 controls. 
Mortality Data From the municipal registry, the vital status of the participants, available until January 1, 2005, was obtained for all participants on a biweekly basis. Furthermore, the general practitioners in the suburb of Ommoord reported deaths on a continuous basis. Reported deaths were verified by specially trained study personnel who checked the medical records.9 Mortality data on participants were available in 100% of the cases. The cause of death was coded according to International Classification of Diseases version 10 (ICD-10) criteria.IO Certainty of cause of death was also recorded and was classified as either certain or probable in 84% of the cases. A participant was determined to have died of cardiovascular causes when an ICD-10 criterion of cardiovascular death was met (ICD-10 codes: I08; Il2; 113; 120; 121; 121.3; 121.9; 124; 125; 125.9; 126; 126.9; I31; I35; I33; I33.0; I35.0; I35.5; 142; 146; 147; 148; 149; ISO; 150.0; IS0.9; 170; 170.9; 171; 171.8; 172; 173; 174; 179; 180) and cause of death was classified as either certain or probable. IO Participants were followed up from date of entry until the date of death, or January 1, 2005, whichever came first. 
Medication Data All seven pharmacies in the Ommoord region provided data on use, duration of use, date of first prescription and type of topical beta-blockers. These pharmacies were all fully auto­mated and used a single computer network to register all prescriptions for drugs used from January 1, 1991, onward. Topical Beta-blockers and Mortality 103 
Cardiovascular Data For each participant, data on cardiovascular and cerebral disorders (that is, hypertension, heart failure, atrial fibrillation, myocardial infarction, angina pectoris, diabetes mellitus, stroke, dementia, cholesterol levels and smoking habits) were recorded. Cardiovascular data were obtained by means of interviews with the participants, electrocardiogram readings, blood cholesterol levels, and non-fasting and fasting serum blood glucose levels at baseline and during follow-up. Cardiovascular events between baseline and follow-up were recorded via a continuous monitoring system through automated linkage with general practitioner information systems. Hypertension was defined as the use of antihypertensive medication for the indication of hypertension or as a systolic blood pressure of 140 mmHg or more, or a diastolic pressure of 90 mmHg or more.1 U2,13• 14,15,I6,17 
Data Analyses Differences in the characteristics between participants with and without use of topical beta­blockers were evaluated with the chi-square test for dichotomous variables and the t-test for continuous variables. Associations between long-term use of topical beta-blockers and mortality were assessed using Cox proportional hazards models, expressed as hazard ratios (HR). All analyses were adjusted for sex and age. Potential confounding by the presence of cardiovascular diseases, cerebrovascular disease, dementia or smoking habits was evaluated as well. Any factor for which the difference in occurrence between users and non-users showed a P-value of less than 0.2 in the univariate comparison was considered as a potential confounder and included in the Cox proportional hazards model. 18 A possible dose-response relationship was evaluated using trend analyses. To this end, participants were divided into three groups based on the duration of use of topical beta-blockers: no beta-blocker usage, less than 5 years of beta-blocker usage, and 5 years or more of beta-blocker usage. All analyses were performed for both all-cause mortality and cardiovascular mortality. The long-term analysis presented above was limited to topical beta-blocker use before or at baseline (following the methods of the Blue Mountains Eye Study), ignoring beta-blocker use after baseline. For that reason, we also performed a time-dependent Cox proportional hazards analysis on all participants of the Rotterdam Study (n=7983). Outcome measure was all-cause mortality between the onset of the Rotterdam Study (1990-1993) and January 1, 2005. In this period, 3814 participants died. Topical beta-blocker use was coded both as the total number of prescriptions during life (cumulative use) and as any prescription in the last three months of life (current use). 104 Chapter 6 
The influence of topical beta-blockers on serum cholesterol levels was examined using mul­tiple linear regression analysis adjusted for age and sex. The short-term effects of topical beta-blockers on mortality were examined using a chi­square test. Potential confounding by the presence of cardiovascular diseases, cerebrovas­cular disease, dementia or smoking habits was evaluated using chi-square tests. Stratification for significant confounders was performed. All statistical analyses were performed using SPSS software for Windows version 14.0.2 (SPSS Inc., Chicago, IL), except for the time-dependent Cox analyses, where SAS version 9.1 (SAS institute Inc., Cary, NC) was used. A P  value of 0.05 or less was considered as statistically significant. Topical Beta-blockers and Mortality 105 
Results 
Long-Term effects of topical beta-blockers 3842 participants with a mean age of 72 years (Standard Deviation [SD] 7 years) at the onset of this analysis (1997-1999) were followed up until January l, 2005. Table 1 presents the baseline characteristics of these participants. During follow-up 709 (18%) of the partici­pants died, of whom 135 (3.5%) of a cardiovascular cause. Table 2 shows the cause of death for participants in the long-term effect study. Table I Baseline characteristics of participants in the long-term effect study with and without topical beta-blocker usage. Topical beta-blockers No topical beta-blockers (n=228) {n=3614) Gender (% female) 53.5 58.1  Median age (yrs, SD) 75 (8) 72 (7) Oral beta-blockers (%) 29.8 30.8 Heart failure (%) 8.3 6.6 Myocardial infarction (%) 3.9 4.2 Atrial fibrillation (%) 1 .3 Angina pectoris (%) 33.3 27.2 Hypertension (%) 69.7 60.7 Smoking (%) 8.8 16.6 Diabetes mellitus (%) 18.4 1 1 .3 Stroke (%) 4.8 4.3 Dementia (%) 2.6 1 .9 Pvalue 0.198 0.001 0.821 0.375 1 .000 0.868 0.051 0.008 0.003 0.002 0. 8 1 1  0.605 Topical beta-blockers were used by 228 (6%) participants, of whom 53 (23.2%) died during follow-up. Twelve (5.3%) participants who used topical beta-blockers died of cardiovascular causes. Table 3 presents the results of the Cox proportional hazards analysis adjusted for age and sex for all-cause mortality (Table 3A) and for cardiovascular mortality (Table 3B). Topical beta-blocker use was not associated with either all-cause mortality or cardiovascular mortality, when adjusted for age and sex. Potential confounders were selected using the univariate comparisons from Table 1. As can be seen in this Table, the proportions of systemic hypertension (0.69 vs. 0.61; P = 0.008), diabetes mellitus (0.18 vs. 0.11; P = 0.002) and angina pectoris (0.33 vs. 0.27; P = 0.051) were higher in the participants using topical beta-blockers, and the proportion of current smokers (0.09 vs. 0.17; P = 0.003) was lower in the group of participants using topical 
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Table 2 Cause of death {ICD-10) for the long-term effect analysis. Only deaths whose cause was deemed certain or probable were classified. 709 participants died during follow-up: 53 of 228 {23.2%) participants who were using topical beta-blockers and 656 of 3614 (18,1%) of those participants who did not use topical beta-blockers. Cause of death Beta-blocker users Non-users 
(53) (656) Cardiovascular disease 12 (22.6%) 123 (18 .7%) Neurological disease 6 ( 1 1 .4%) 98 (14.9%) Stroke 3 (5.7%) 58 (8.8%) Dementia 1 ( 1 .9%) 26 (4.0%) Other Neurological disease 2 (3.8%) 14 (2. 1%) Cancer 9 (16.9%) 209 (31.9%) Pulmonary disease 1 (1 .9%) 41 (6.3%) Trauma 1 (1 .9%) 22 (3.4%) Gastrointestinal disease 0 20 (3.0%) Infectious disease 0 10 (1.5%) Autoimmune disease 0 1 (0.2%) Renal disease 0 1 (0.2%) Other 7 (13.2%) 33 (5.0%) ICD-10 = International Classification of Diseases version 10. Table 3 Associations between topical beta-blockers and all-cause (A) and cardiovascular {B) mortality, adjusted for age and sex. A. All-cause mortality Hazard Ratio 95.0% Confidence Interval Topical beta-blockers 0.906 0.683 - 1 .201 Gender 0.513 0.442 - 0.595 Age 1 . 1 12  1 . 100 - 1 . 123 B. Cardiovascular mortality Hazard Ratio 95.0% Confidence Interval Topical beta-blockers 1 .012 0.556 - 1 .844 Gender 0.354 0.249 - 0.502 Age 1 . 124 1 .099 - 1 .150 P value 0.492 <0.001 <0.001  P value 0.968 <0.001 <0.00 1  Topical Beta-blockers and Mortality 107 
Table 4 Associations between topical beta-blockers and all-cause (A) and cardiovascular (B) mortality, adjusted for age, sex, current smoking, hypertension, diabetes mellitus and angina pectoris. A. All-cause mortality Hazard Ratio 95.0% Confidence Interval Topical beta-blockers 0.943 0 .7 1 1  - 1 .252 Gender 0.533 0.459 - 0.620 Age 1 . 1 15 1 . 1 03 - 1 . 127 Smoking 1 .903 1 .575 - 2.299 Hypertension 1 .055 0.898 - 1 .240 Diabetes mellitus 1 .461 1 . 198 - 1 .782 Angina pectoris 1 . 136 0.967 - 1 .335 B. Cardiovascular mortality Hazard Ratio 95.0% Confidence Interval Topical beta-blockers 1 .018 0 .558 - 1 . 858 Gender 0.351 0.246 - 0.502 Age 1 . 127 1 . 100 - 1 . 154 Smoking 1 .8 16 1 . 159 - 2.845 Hypertension 1 .097 0.745 - 1 .595 Diabetes mellitus 1 .748 1 . 147 - 2.663 Angina pectoris 1 .738 1 . 225 - 2.465 P value 0.687 <0.001 <0.001 <0.001 0.515 <0.001 0.120 P value 0.954 <0.001 <0.001 0.009 0.628 0.001 0.002 beta-blockers. For this reason systemic hypertension, diabetes mellitus, angina pectoris and current smoking were added to the model. Table 4 presents the resulting model. No significant association between all-cause mortality and topical beta-blocker use ( Table 4A) or between cardiovascular mortality and topical beta-blocker use ( Table 4B) was found when adjusted for age, sex, systemic hypertension, diabetes mellitus, angina pectoris and current smoking. These analyses were also performed for baseline usage of timolol, that is, after excluding other topical beta-blockers like betax­olol. No significant relationship between baseline timolol usage and either all-cause mor­tality (HR 0.89; 95% confidence interval 0.63-1.25; P = 0.495) or cardiovascular mortality (HR 0.60; 0.24-1.47; P = 0.259) was found. To investigate any possible masking of an association between topical beta-blocker use and mortality caused by the duration of use of topical beta-blockers, a trend analysis was 10 8 Chapter 6 
performed to show whether a dose-response relationship existed. No associations were found between the duration of beta-blocker usage and either all-cause mortality (HR 1.03; 0.86-1.25; P = 0.735) or cardiovascular mortality (HR 1.14; 0.78-1.67; P = 0.504), when adjusted for age, sex, systemic hypertension, diabetes mellitus, angina pectoris and cur­rent smoking status. These analyses performed with the duration of timolol usage as the dependent variable did not show any significant relationship either. A time-dependent Cox proportional hazards analysis, taking into account not only topical beta-blocker use before and at baseline but also after baseline, did not reveal any harmful effect of topical beta-blockers, neither for cumulative use (HR 0.994; 0.990-0.999) nor for current use (HR 0.610; 0.493-0.756). These analyses were adjusted for age, sex, sys­temic hypertension, diabetes mellitus, angina pectoris and smoking. The same analyses performed after the exclusion of participants already using topical beta-blockers at the onset of the Rotterdam Study, aiming to avoid a bias towards beta-blocker survivors, did not uncover any harmful effect either (cumulative use: HR 0.992; 0.989-0.997; current use: HR 0.492; 0.373-0.649). No significant effect for topical beta-blocker usage on serum HDL-cholesterol levels was found, when adjusted for age and sex (adjusted R2 0.023; P = 0.68). 
Short-term effects of topical beta-blockers The short-term effects of topical beta-blockers on mortality, that is, death shortly after the initial use of topical beta-blockers, was investigated by comparing the proportion of beta­blocker users who died within three months after the first prescription to the mortality among age-matched controls within a similar period. Of the 484 participants who started using a topical beta-blocker after the onset of the Rotterdam study (1990-1991), four (0.8%) died within three months. The mean age at the time of the first prescription was 74 years (SD 7 years). In the 4700 controls who did not receive a topical beta-blocker, 65 (1.4%; 
P = 0.31) died within three months after a point in time (95 month after the onset of the Rotterdam Study) when their mean age averaged 74 years (SD 8 years), that is, when they were age-matched with the incident beta-blocker users. Smoking appeared to be the only possible confounder that had a different occurrence in incident topical beta-blocker users (38 of 484, that is, 7.9%) and non-users (645 of 4700, that is, 13.7%; P < 0.001). Therefore, the analysis was stratified for smoking. No association between topical beta-blocker therapy and mortality within three months was found (smokers: 0 of 38 versus 16 of 645, P = 0.33; non-smokers: 4 of 446 versus 49 of 4055, P = 0.56). Table 5 shows the causes of death for participants in the short-term effects study. Topical Beta-blockers and Mortality 109 
Table 5 Cause of death (ICD-10) for the short-term effect analysis. Only deaths whose cause was deemed certain or probable were classified. Incident beta-blocker users (n=4) Subject 1 Subject 2 Subject 3 Subject 4 
Age-matched controls (n=65) Cause of death Cardiovascular disorders Neurological disease Stroke Dementia Neurological disorders Cancer Pulmonary disorders Trauma Other Unknown Time of death(days after first prescription) 4 30 40 88 Number of deaths 10 (15.4%) 15 (23.1%) 8 (12.3%) 3 (4.6%) 4 (6.2%) 21(32.3%) 4 (6.2%) 1 (1.5%) 2 (3.0%) 12 (18 .5%) 
ICD-10 = Internacional Classification of Diseases version 10. 1 10 Chapter 6 Cause of death cerebral infarction pulmonary embolism stroke unspecified chronic myeloid leukemia 
Discussion This study did not demonstrate either a long-term effect or a short-term effect on mortality from topical beta-blocker use. Neither did the use of a topical beta-blocker influence serum HDL-cholesterol levels. Clinically speaking, these findings should allow us to continue to use topical beta-blockers as a first-line anti-glaucoma medication. Our results are apparently in conflict with the results found in the Blue Mountains Eye Study.3 In that study, the possibility of a harmful effect from topical beta-blockers in terms of mortality was shown. This effect, however, was not shown in their 88 baseline users (HR 1.47; 0.90-2.41); only in a trend analysis was long-term use of topical timolol associated with an increase in cardiovascular mortality. In our study, this long-term harmful effect on cardiovascular mortality could not be reproduced, neither for all topical beta-blocker nor for timolol use alone. Most of the findings from the Blue Mountains Eye Study and our study, however, display amply overlapping confidence intervals, and therefore these studies should not be considered conflicting. The confidence interval from the Blue Mountains Eye Study mentioned above (0.90-2.41), for example, should be compared to our 0.56-1.86 (Table 4B). Our results do corroborate the results from the OTHS study and the EMGT study. 1 •2 Furthermore, our results are in line with a myriad of earlier data provided by numerous randomized controlled trials on the use of systemic beta-blockers for many dif­ferent types of cardiovascular disorders. In fact, these studies almost unanimously showed a beneficial effect from the use of beta-blockers in terms of mortality.4•5•6 The upper limits of our 95% confidence intervals, 1.25 for all-cause mortality and 1.86 for cardiovascular mortality (Table 4), demonstrate that a doubling of the risk of cardiovascular mortality can be ruled out, but not a 50% increase. For all-cause mortality, an increase in risk exceeding 25% seems to be unlikely, and the results of our time-dependent Cox proportional hazards analyses even support the absence of any harmful effect. Another possibly important effect of timolol could be a short-term effect on mortality for topical beta-blockers, that is, death shortly after the onset of topical beta-blocker use. This theoretically may be a consequence of, for example, systemic hypotension or an asthma attack. The Blue Mountains Eye Study did not address this issue. We could not demon­strate any short-term negative effects on mortality for topical beta-blockers. In our study, four of 484 participants (0.8%) died within three months of collecting their first prescrip­tion for a topical beta-blocker. A sensitivity analysis revealed that, given 65 of 4700 (1.4%) deaths in the control group, 13 of 484 (2.7%) deaths among the cases would be needed to reach a statistically significant increased risk. Changing the definition of short-term effects by prolonging the time period after the first prescription, with the aim of increasing the number of short-term deaths, would not be prudent. This would in fact decrease the prob­ability that the death was really related to the start of topical beta-blocker use. Topical Beta-blockers and Mortality 1 1 1  
Another negative effect on mortality from topical beta-blockers may be a negative effect on serum lipid levels caused by topical beta-blockers.19 An earlier report on systemic timolol, however, has actually shown a reduction in the mortality of patients using systemic timolol. 20 The conclusion was that any possible deleterious effects from systemic timolol on serum lipid levels did not cancel out its protective effects. For this reason, even if a negative effect on HDL-cholesterol from topical beta-blockers had been found, one could speculate whether this would really constitute a clinically relevant finding. In our study, we could not demonstrate any negative effects on serum HDL-cholesterol levels from topical beta­blocker use. The strength of our current study lies in the study design. The Rotterdam study is a long­term prospective population-based study. Pharmacological data were collected through a fully automated system, which yields a very accurate and complete history of medication use. Mortality data were also collected through an automated system that resulted in com­plete data on vital status. One limitation of this study is that, although a very accurate pharmacologic prescription history was available, it is unknown whether patients actually took their prescribed medication. Another possible limitation might lie in the percentage of participants with a confirmed cardiovascular death. This percentage was low: only 19.3% of all deaths were classified as cardiovascular deaths in our study as compared to 35.7% in the Blue Mountains Eye Study report. There are several reasons for this discrepancy. First, the average Dutch cardiovascular mortality figure is 30.8%, which is also lower than the Blue Mountains Eye Study percentage. 21 Second, the percentage of confirmed cardiovascular mortality was also lower as a consequence of our choice to only classify deaths as cardio­vascular when the cause of death was deemed certain or probable. This choice was made to prevent misclassification. Since the analyses of all-cause mortality also did not show any effect, it is highly unlikely that the low percentage of cardiovascular deaths would have any influence on our final conclusion. One last possible effect on mortality from topical beta-blockers is mortality after the with­drawal of beta-blockers. If one abruptly stops using beta-blockers, this can raise heart rate and blood pressure, which in turn may decrease coronary artery perfusion, which results in an increase in myocardial ischemia. The resulting myocardial ischemia may increase the probability of dying. In our study the issue of withdrawal of beta-blockers was not addressed. This was not performed because it was not possible to gain data on withdrawal of beta-blockers. Although all the Ommoord pharmacies are connected to one computer system and the pharmaceutical history of each Rotterdam-study participant is virtually complete, these data consist of prescriptions. Therefore, it is not possible to determine the difference between a participant dying while using topical beta-blockers and a participant dying because of suddenly stopping the use of topical beta-blockers. 1 12 Chapter 6 
In conclusion, our current report has shown no association between the use of topical beta-blockers and mortality. These results are consistent with earlier ophthalmological and cardiovascular trials. On the basis of all this information, the authors believe that topical beta-blockers can safely be employed as a first-line therapy for glaucoma. Topical Beta-blockers and Mortality 1 13 
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In the five studies contained in this thesis, several controversies on the diagnosis of and therapy for glaucoma have been addressed. The first part of this thesis consisted of three studies that aimed to improve existing technologies for diagnosing glaucoma. The latter part consisted of two chapters in which the controversies surrounding beta-blockers, one of the most widely used class of ocular and cardiovascular medications, was discussed. In this chapter, the main findings of each study will be discussed in the light of current knowledge. The definition of visual field defects on standard automated perimetry Standard automated perimetry (SAP) is the most ubiquitous method of visual field exami­nation in clinical use in the Western world today. In spite of this, no classification system for distinguishing all types of visual field defects on SAP has ever been developed. Earlier classification systems either described only a limited number of visual field defects or were so cumbersome that they were not suitable for everyday clinical use.1-3 In Chapter Two, we described the development and implementation of the static auto­mated perimetry classification system (SAPCS). SAPCS is an unambiguous classification system for all types of visual field defects measureable by a commonly used SAP device, the Humphrey Visual Field Analyzer (HFA; Carl Zeiss Meditec AG, Jena, Germany). The system we developed has proven to be able to diagnose visual field defects correctly, when compared to the presumed cause of the abnormality. The principle advantages of SAPCS lie in the fact that it is easy to learn and does not take much time to perform once one has mastered it. This was shown in Chapter Two, when an independent ophthalmologist, after receiving instruction for half an hour, graded 100 visual fields in 1.5 hours. Only one visual field was classified differently by this ophthalmol­ogist, when compared to the classification by one of the designers of the system. The ease of learning comes from the unambiguous design of SAPCS. Unlike the judging of visual field results subjectively, just applying SAPCS automatically leads to a classification of a visual field defect. In addition, no software needs to be acquired to put SAPCS into practice. For these reasons SAPCS can be implemented in everyday clinical practice and be an extra tool for practicing ophthalmologists in diagnosing visual field defects. Another advantage of SAPCS lies in the fact that, although it was developed on the HFA perimeter, from the outset one of the goals of this system was to make it platform inde­pendent. Because SAPCS does not take any HFA-specific parameters into account, it should be easy to carry SAPCS over to other types of perimeters, which then makes a broad implementation in ophthalmic practice possible. Since the devices from different General Discussion 1 19 
manufacturers use different grids (for instance the standard 24-2 and 30-2 programs on the HFA use a fixed space-grid pattern for the central 24 or 30 degrees, whereas the Octopus Perimeter uses a polar grid pattern in its standard Gl/G2 program),4 some modifications will be necessary before SAPCS can be used on other perimeters. One drawback of our study is that participants were aged 55 years and older. Although this is the age group of patients in a typical ophthalmic out-patient department, it also means that some relatively common visual field defects in younger age groups, for instance, a com­pression of the optic chiasm, did not occur in this population. Therefore, the performance of SAPCS needs to be explored further in a younger population. Frequency doubling technology algorithms compared Frequency doubling technology (FDT ) was introduced as a form of perimetry that isolated a subset (My-cells) of the magnocellular cells in the retina and could, due to a reduced redundancy in these cells, potentially be able to detect glaucomatous visual field defects earlier than standard automated perimetry.5-7 In clinical practice, the main advantage of the FDT system, which has larger stimuli for fewer locations than standard automated perimetry does, is that it is easy to use, is fast and has no significant learning-effect. 6•8 These properties make the FDT very suitable for the detection of glaucomatous visual field defects in glaucoma suspects. However, although very many algorithms for the classification of FDT results have been described, there has been no consensus on the best way to judge FDT results.9-15 In Chapter Three, all the published algorithms for judging Frequency Doubling Technology Perimetry (FDT ) results were compared. We showed that the simplest algorithm of all, that is, simply counting the number of abnormal test locations, was also the best way of judging FDT results. At first glance these results may seem odd. Why would an algorithm that simply counts defects without taking the location of the defect into account perform in a similar fashion to algorithms that have been specifically designed to add weight factors to those locations where glaucomatous visual field defects are expected to develop first? Two possible explana­tions for this lie either in the FDT stimulus itself or in the size of the FDT stimuli. The explanation based on the nature of the stimulus goes as follows. If we assume that the FDT perimeter stimulus isolates the My-cells, it is possible that the anatomical layout of My-cells in the retina is different from that of other ganglion cells. This would mean that the classic glaucomatous defects, which are defined on the basis of white-on-white perimetry, are not 120 Chapter 7 
the preferred locations for glaucomatous defects in My-cells, and that algorithms with weight factors based on these classic glaucomatous defects would not have any advantage over algorithms without these weight factors. Our results imply that all My-cells in the cen­tral 20 degrees of the visual field would be equally susceptible to glaucomatous damage. On the other hand, questions about whether FDT perimetry truly isolates My-cells have been raised in the literature. It is possible that FDT perimetry tests the same cells as standard white-on-white perimetry. In that case, one would normally expect algorithms with weight factors to be beneficial. The main difference between normal standard automated perimetry and FDT would then be in the size and location of the test stimuli. The test stimuli of the FDT are so large that our result indicates that with such large stimuli it is simply not advan­tageous to define any preferential locus of damage. In the newest version of the FDT Perimeter, The Humphrey Matrix, the stimulus size has been reduced in order to aid in detection and follow-up of glaucoma patients. 16 It is cur­rently unknown whether adding weight factors to specific stimulus locations in that instru­ment would help in the detection of glaucoma and whether the location of these weight factors would be the same as in white-on-white perimetry. It is even unknown whether this reduction in stimulus size would aid in glaucoma detection. 16 One very large advantage that our result has is that a simple algorithm to define abnor­mality reduces the chances of diagnostic error. This study has led to a follow-up study by Stoutenbeek and colleagues in which full-threshold FDT perimetry was compared with an even faster screening mode of FDT perimetry, and that study showed that this simple algorithm could be applied to a screening mode without loss of sensitivity or specificity. 17 Since these two studies, the FDT with this algorithm for abnormality has been implemented successfully in an out-patient clinic for the detection of glaucoma run by optometrists at the University Medical Center Groningen. The GDx anterior segment compensation investigated The fourth chapter describes our study aiming to improve the diagnostic accuracy of the GDx nerve fiber analyzer, a device that measures the thickness of the retinal nerve fiber layer in vivo by using polarized light and measuring retardation caused by birefringence of the retinal nerve fiber axons. 18 In this study, we tried to compensate for the interference effects of anterior segment bire­fringence, which are often inadequately corrected by the fixed anterior segment compen­sator that is incorporated in the GDx Nerve Fiber Analyzer. 19 General Discussion 121 
To this end a GDx scan of the macula was performed. To obtain such a scan the GDx machine is simply aimed at the macular region instead of the peripapillary area. In 2000, Greenfield reported that a GDx scan of the macular region was normally an even blue color due to the radial distribution of the nerve fibers in the macula.19 Any change in this pat­tern pointed to an excess amount or change of direction of anterior segment birefringence. Based on GDx macular scan results, we subsequently tried to correct the interpretation of the peripapillary GDx scan. Our results showed that there was no significant difference between the macular scan values of patients who were correctly or falsely classified by the GDx peripapillary scan. Therefore, it was not possible to compensate for inadequately compensated anterior segment birefrin­gence by performing a macular scan. This result has an implication on two levels, scientific and clinically. On a scientific level, it means that in contrast to what was stated in earlier reports, an inadequately compensated anterior segment birefringence cannot be a major cause of GDx misclassifications. This was apparent from the earliest report in which a variable anterior segment compensator was fitted to a GDx Nerve Fiber Analyzer. In this report only a marginal improvement in performance was noted. 20 Despite these results, a new version of the GDx with variable anterior segment compensa­tion was subsequently developed. This later version of the GDx with a variable anterior segment compensator showed some improvement in diagnostic accuracy. It is possible that these slight improvements in diagnostic accuracy using the new version of the GDx may be attributed in large part to other concurrent improvements in the machine such as an internal fixation target and faster scan acquisition times. Whether a variable anterior-seg­ment compensation is an advantage, or whether it may even be a disadvantage because of greater variability between measurements when used in follow-up of patients with glau­coma, remains unanswered. The clinical value of our study lies in the fact that it has shown that the GDx with a fixed anterior segment compensator can be used clinically without taking macular scan results into account. Although a newer version of the GDx is available, these results remain clini­cally relevant, because all current longitudinal studies are based on the GDx with a fixed anterior segment compensator. 122 Chapter 7 
Antihypertensives and glaucoma In Chapter Five, we investigated the effects of blood pressure lowering medication on the incidence of glaucoma, with special attention to the effects of systemic beta-blockers. In the literature, several publications have appeared suggesting that systemic beta-blocker use causes a reduction in blood flow to the optic nerve and via that route may exacerbate glaucomatous damage. 21 •22 In addition, several reports have asserted that systemic calcium channel antagonists may increase blood flow to the optic nerve and may be beneficial for glaucoma patients. 23•24 In contrast, our study showed no effects from systemic beta-blockers on the development of glaucoma (in effect, there was almost a statistically significant protective effect of systemic beta-blockers) and calcium channel antagonists seemed to increase the risk of glaucoma. No other systemic antihypertensive medication classes had any effect on the development of glaucoma. These findings are both clinically and scientifically relevant. Scientifically, our results are intriguing because they conflict with what was a commonly held view, that is, that calcium­channel antagonists did not seem to have any beneficial effect on the development of glau­coma, whereas systemic beta-blockers did. This result theoretically may imply that even a slight intraocular pressure reduction, as is obtained with the use of systemic beta-blockers, outweighs any effect systemic antihypertensives may have on ocular blood flow. However, the effect of beta-blockers did remain unchanged after correcting for intraocular pressure. Several studies have indicated that patients with glaucoma have an abnormal autoregu­lation of optic nerve blood vessels and may, therefore, respond differently to changes in hemodynamics.22 This abnormal autoregulation may result in glaucomatous damage occur­ring as a result of moments of systemic hypotension. If this was an important factor in the development of glaucoma, one would expect that administering systemic antihypertensives, and thus changing ocular blood flow, would have resulted in at least a small but measurable effect. But this could not be demonstrated, not even in the group of participants that had normal tension glaucoma, historically considered to be the group most likely to suffer from altered hemodynamics in the optic nerve. The clinician viewing these results may be reassured that the treatment of systemic hyper­tension does not greatly enlarge or diminish a patient's chance of developing glaucoma, since the odds ratios for most antihypertensives were close to one. This means that cur­rently our study does not provide any evidence for changing treatment regimens for patients with systemic hypertension, especially since there is no reason to prefer calcium channel antagonists over beta-blockers for fear of glaucoma. In addition, the prescription of calcium General Discussion 123 
channel antagonists to prevent glaucoma cannot be recommended based on our study. As our study did not specifically investigate the effect of systemic antihypertensives on the pro­gression of established glaucoma, we cannot make any direct recommendations concerning the treatment of systemic hypertension in patients with established glaucoma. However, when extrapolating our results one can state that, with our current knowledge, treatment paradigms do not need to be altered. Topical beta-blockers and mortality The effect of topical beta-blockers on mortality was investigated in Chapter Six. On this subject, there are also conflicting reports in the literature. Our study was brought about by the recent publication of a population-based study in Australia that suggested topical beta­blockers might increase cardiovascular mortality. 25 Our study results did not reproduce this result; we found no long-term effect from topical beta-blockers on either all-cause or cardiovascular mortality. In addition, we did not find any increase in mortality shortly after initiating topical beta-blocker therapy. One major difference between our study and the Australian study was the way medication data was collected. Data on medication use in the Australian study were based on question­naires in which participants were asked what types of medication they had used during the previous five years. This approach is prone to bias due to incorrect reporting. In our study medication data was collected from a computer network to which all seven pharmacies in the Ommoord region were connected. In this computer network all prescriptions that were delivered to participants in our study were recorded from January first, 1991, onward. In this way we could obtain a very accurate medication history for each participant. Our results are in line with many other cardiovascular studies. 26-28 In cardiovascular medi­cine, beta-blockers are used therapeutically for many disorders. Ophthalmic beta-blockers are, however, mostly unselective beta-blockers in contrast to the majority of beta-blockers that are used to treat cardiovascular disorders. Therefore, our study was clinically relevant; we showed that even the unselective beta-blockers that are used in ophthalmology did not seem to have any effect on mortality. Our result was in line with a study from Norway that showed that systemic timolol (an unselective beta-blocker) also has a beneficial effect on cardiovascular disorders. 29 This means that topical beta-blockers can continue to be used as a first-line therapy in the treatment of glaucoma. 1 24 Chapter 7 
The major limitation of our study was that, because of its population-based design, we could not determine the effects of suddenly discontinuing topical beta-blockers, which could theoretically have a negative effect on myocardial perfusion. One other observation that can be made based on our study is that the history of ophthalmic beta-blockers closely mimics the history of systemic beta-blockers. Systemic beta-blockers were greeted with great enthusiasm when they appeared on the market, but reports on their side effects soon after gave systemic beta-blockers a bad reputation and use declined, which has only begun to subside over the last decade now that the positive results of the use of beta-blockers in higher-quality trials has become available. Ophthalmic beta-blockers are currently going through the same cycle. When ophthalmic beta-blockers became available they were quickly adopted into clinical practice, as other classes of intraocular pressure­lowering medications at that time had severe consequences for a patient's quality of life. 30 After two years, reports and studies on life-threatening side effects began to appear, 31 which led to reduced use of topical beta-blockers. Most studies on the side effects of topical beta­blockers were either case reports or case series. When results from randomized clinical trials became available they showed no significant difference in death due to topical beta-blockers use.32-33 This has now been corroborated by our results. The importance of this finding is that topical beta-blockers are, with prostaglandin ana­logues, the most potent intraocular pressure-lowering medications in use today. 34 Also, all combination preparations use a beta-blocker as one of their components. Our results indicate that topical beta-blockers, when used judiciously, can be prescribed without fear of increasing the chance of mortality in a patient. Once more of these results become avail­able, the cycle of topical beta-blockers will follow that of systemic beta-blockers, and topical beta-blockers will not be withheld from patients, who could benefit greatly from their use, out of unsubstantiated fear of complications. Conclusion In conclusion, the studies contained in this thesis have yielded several results that can be easily implemented in clinical practice. Because this thesis was written over a period of six years, several of the earlier study results have already been put into clinical practice. Both the algorithm for judging FDT results and the GDx macula scan are in clinical use at this moment. The results from the studies on beta-blockers in this thesis have helped guide clinical decision-making. Although treatment algorithms for both systemic hypertension and glaucoma treatment did not need to be altered based on our studies, the studies did help in reassuring that no unnecessary harm was being done to patients by treating them with beta-blockers. The second chapter of this thesis was written last; therefore, the results, General Discussion 125  
mainly with respect to the development of the static automated perimetry classification system, have not been implemented in clinical practice as of today. However, as no invest­ment in equipment or software is required, it is possible that the use of the static automated perimetry classification system will become reality in the near future. Every study raises at least as many questions as it answers. And further research is both needed and on-going in all the fields that were described here. This thesis does, however, provide solutions to several clinical problems in relation to glaucoma, and these are solu­tions that are easy to apply in daily clinical practice. 126 Chapter 7 
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Glaucoom is een groep van aandoeningen die gekenmerkt wordt door een progressief ver­lies van zenuwvezels in de oogzenuw met als gevolg verlies van het gezichtsveld. De belang­rijkste risicofactor, en op dit moment tevens het enige aangrijpingspunt voor de behande­ling van glaucoom, is een te hoge oogdruk. Niet alle mensen met een hoge oogdruk hebben glaucoom. Als er geen schade aan de oogzenuw en gezichtsveld is opgetreden bij iemand met een bovennormale oogdruk (een oogdruk boven 21 mmHg), dan wordt er gesproken van oculaire hypertensie. Naar schatting hebben in 2010 wereldwijd 60 miljoen mensen glaucoom, waarvan 8 mil­joen blind aan beide ogen zijn. Glaucoom is daarmee na staar de op een na belangrijkste oorzaak van blindheid. Schade aan het gezichtsvermogen als gevolg van glaucoom is, in tegenstelling tot staar, onherstelbaar. Dit maakt glaucoom de belangrijkste oorzaak van blijvende blindheid in de wereld. In Nederland heeft ongeveer 1 % van de bevolking primair openkamerhoek glaucoom, het meest voorkomende type glaucoom. Omdat glaucoom in de vroege stadia meestal symptoomloos verloopt, wordt de diagnose glaucoom gesteld op basis van het aspect van de oogzenuw bij fundoscopie en afwijkingen van het gezichtsveld. Afwijkingen van het gezichtsveld worden vastgesteld met behulp van perimetrie, de laatste decennia meestal statische automatische perimetrie. Een probleem bij de diagnostiek van glaucoom is dat de aanblik van de oogzenuw bij fundoscopie erg veel variatie tussen individuen vertoont en dat het onderzoek van het gezichtsveld met statische automatische perimetrie (SAP) voor de patient een lastige test is. Om deze reden zijn de afgelopen decennia een aantal diagnostische apparaten ontwikkeld die de clinicus kunnen ondersteunen, waarvan de GDx Nerve Fiber Analyzer (GDx) voor het beoordelen van de oogzenuw en de Frequency Doubling Technique (PDT) als alternatief voor perimetrie, de meest gebruikte zijn. Zoals eerder genoemd is het verlagen van de oogdruk de enige therapeutische interventie met een in gerandomiseerd klinisch onderzoek bewezen effect op glaucoom. Een verlaging van de oogdruk voorkomt het ontstaan van glaucoom bij mensen met oculaire hypertensie, en remt de mate van achteruitgang van het gezichtsveld bij mensen met glaucoom. Methoden om de oogdruk te verlagen zijn chirurgisch, medicamenteus (oogdruppels of tabletten) en middels laserbehandeling. De overgrote meerderheid van de glaucoompatienten in Nederland wordt met oogdruppels behandeld. Een van de meest voorgeschreven middelen om de oogdruk te verlagen zijn, sinds hun introductie in 1978, de topicale beta-blokkers. Een recente meta-analyse heeft uitgewezen dat therapie met topicale beta-blokkers de oog­druk met gemiddeld 27% verlaagt en dat daarmee oogheelkundige beta-blokkers samen met prostaglandine-analogen de meest effectieve oogdruk verlagende middelen zijn. Samenvatting 131 
Naast gunstige effecten van medicatie wordt in de medische literatuur een aantal middelen beschreven die de bloedvoorziening van de oogzenuw nadelig zou kunnen bei'.nvloeden en op die wijze het ontstaan van glaucomateuze schade aan de oogzenuw zou kunnen bevorderen. Van deze middelen, waarvan antihypertensiva (onder andere beta-blokkers) de belangrijkste zijn, wordt beweerd dat zij het ontstaan van glaucoom kunnen bevorderen. Van calcium antagonisten wordt daarentegen beweerd dat zij door hun vaatverwijdende eigenschappen mogelijk een gunstig effect op glaucoom hebben. Dit proefschrift bestaat uit twee delen. Het eerste deel, bestaande uit de hoofdstukken 2, 3 en 4, richt zich op glaucoomdiagnostiek. In dit deel van het proefschrift wordt nagegaan wat de mogelijkheden zijn tot verbetering van de prestaties van SAP, GDx en FDT voor glaucoomdiagnose. Het tweede deel, bestaande uit de hoofdstukken 5 en 6, richt zich op de veiligheid van medicatie. Sinds zijn ontstaan in 1975 is statische automatische perimetrie in hoog tempo een van de pijlers van de hedendaagse glaucoomdiagnostiek geworden. Het is zelfs zo dat in bijna iedere oogheelkundige praktijk in Nederland een vorm van statische automatische perime­trie (SAP) het standaard gezichtsveldonderzoek voor alle typen aandoeningen is. Ondanks de populariteit van SAP, is tot op heden geen systeem ontwikkeld dat alle typen gezichts­velduitval classificeert. Er zijn wel afzonderlijke classificatie schema's voor glaucomateuze gezichtsvelduitval en bijvoorbeeld gezichtsvelduitval door neurologische aandoeningen, maar deze systemen zijn zo verschillend van aard dat ze niet samengevoegd kunnen worden in een schema. Daarnaast zijn de criteria voor gezichtsvelddefecten in deze systemen veelal erg ingewikkeld, hetgeen gebruik in de dagelijkse praktijk belemmert. In hoofdstuk 2 is beschreven hoe een classificatiesysteem op basis van SAP is ontwikkeld voor alle typen gezichtsvelddefecten. Dit systeem wordt standaard automatische perimetrie classificatie systeem (SAPCS) genoemd. De uitgangspunten voor SAPCS waren dat het eenduidig en eenvoudig te gebruiken moest zijn en alle typen gezichtsvelddefecten moest kunnen benoemen. De ontwikkeling van SAPCS is gebaseerd op klinische en theoretische gronden. Hierna werd SAPCS getest in gezichtsvelden die gemaakt werden tijdens de ERGO studie, een bevolkingsonderzoek onder alle inwoners van 55 jaar en ouder van de wijk Ommoord in Rotterdam. Tijdens deze studie waren zowel statische automatische perimetrie als kine­tische perimetrie volgens Goldmann verricht en werden de oorzaken van gezichtsveld­defecten vastgesteld op basis van de resultaten van Goldmann perimetrie en alle overige beschikbare gegevens. 132 Chapter 8 
Aangetoond is dat met SAPCS alle gezichtsvelden en typen gezichtsvelduitval geclassificeerd kunnen worden. De resultaten vertoonden een redelijke overeenkomst met de resultaten van Goldmann perimetrie en kwamen goed overeen met de oorzaak van de gezichtsveld­defecten. Tevens werd het gebruiksgemak van SAPCS getest. Een onafbankelijk oogarts kreeg na een training van een half uur in SAPCS, opdracht om 100 gezichtsvelden te classificeren volgens SAPCS. Binnen anderhalf uur waren alle 100 beoordeeld en in 99 van de 100 gezichtsvelden was er een volledige overeenstemming met de beoordeling van een van de ontwikkelaars van SAP CS. De conclusie is dat SAP CS eenvoudig te leren en te gebruiken is en dat met SAPCS redelijk betrouwbaar alle typen van gezichtsvelduitval te classificeren zijn. Frequency Doubling Technique (FDT)  is een vorm van perimetrie die in de jaren 90 van de vorige eeuw werd gefotroduceerd. Deze techniek heeft zich een plaats verworven in de opsporing van glaucoom, omdat het, in tegenstelling tot SAP, een test is die snel en een­voudig te verrichten is voor patienten en geen significant leereffect heeft. In de literatuur zijn vele algoritmen verschenen om de FDT te beoordelen. Echter er was tot op heden geen consensus over hoe de uitslagen van FDT onderzoek geinterpreteerd moesten worden omdat onduidelijk was, welk algoritme het beste functioneerde. In hoofdstuk 3 is het onderzoek beschreven, waarin al de beschikbare algoritmen voor beoordeling van de FDT met elkaar vergeleken zijn. Hieruit blijkt dat simpelweg het tellen van afwijkende blokjes zonder reke­ning te houden met de plaats van de uitval de beste resultaten oplevert. Dit resultaat heeft zowel een klinische als een wetenschappelijke betekenis. Klinisch bete­kent het dat de FDT eenvoudig beoordeeld kan worden. Hetgeen een belangrijk voordeel is op een drukke polikliniek. Wetenschappelijk geeft het resultaat weer dat een gezichtsveld onderzoek met een andere stimulus dan SAP, mogelijk andere patronen van uitval geeft. Dir blijkt uit her feit dat de algoritmen met een weegfactor, waarbij de weegfactor veelal geba­seerd is op locaties van glaucomateuze uitval bij SAP, niet tot een beter resultaat leiden. De GDx Nerve Fiber Analyzer (GDx) is een apparaat dat in staat is de retinale zenuwve­zellaag in vivo in beeld te brengen. Hierdoor kan deze techniek de clinicus ondersteunen bij de beoordeling van de oogzenuw. Het werkingsmechanisme berust op her meten van retardatie van gepolariseerd licht. Deze retardatie neemt toe naar mate de dikte van de retinale zenuwvezellaag toeneemt. Echter her hoornvlies (de cornea) en de lens kunnen ook retardatie geven en zo de meting verstoren. Hiervoor is de GDx uitgerust met een vaste corneacompensator. Echter in een belangrijk deel van de bevolking werkt deze cornea­compensator onvoldoende. De werking van de corneacompensator kan beoordeeld worden door een GDx scan van de macula te maken. In hoofdstuk 4 staan de resultaten van her onderzoek, waarbij is nagegaan of de diagnostische prestaties van de GDx te verbeteren zijn Samenvatting 133 
door een maculascan. Het onderzoek toont aan dat er geen verschil bestaat tussen de macu­lascan van personen die door deze techniek goed of verkeerd geclassificeerd waren. Hieruit kan worden geconcludeerd dat de diagnostische prestaties van de GDx niet kunnen worden verbeterd door het maken van een maculascan, en dat een afwijkende corneacompensatie waarschijnlijk niet de meest belangrijke storende factor is bij GDx onderzoek. Hoofdstuk 5 beschrijft het onderzoek naar de relatie tussen het gebruik van antihyperten­siva en het ontstaan van glaucoom. Hiervoor werd gebruik gemaakt van gegevens uit de ERGO studie. Het gebruik van antihypertensiva werd vergeleken tussen deelnemers zonder glaucoom en deelnemers die tijdens de studie glaucoom ontwikkelden. Dit onderzoek toont aan dat de meeste soorten antihypertensiva geen invloed hebben op het ontstaan van glau­coom. Beta-blokkers lijken zelfs een licht beschermend effect op het ontstaan van glaucoom te hebben. Calcium antagonisten lijken als enige groep antihypertensiva de kans op het ontstaan van glaucoom licht te verhogen. Op basis van deze resultaten hoeft de behandeling van hoge bloeddruk niet te worden aangepast om het ontstaan van glaucoom te voorkomen, aangezien beta-blokkers met diu­retica daarin de belangrijkste plaats innemen. Ook de calciumantagonisten hoeven niet uit behandelschema's verwijderd te worden, daar zij veelal gebruikt worden bij moeilijker te behandelen hoge bloeddruk. Bij deze patienten weegt het voordeel van een adequate behandeling van de hoge bloeddruk op tegen een gering verhoogde kans op glaucoom. Het theoretische effect van een verbeterde doorbloeding, dat bij het gebruik van calci­umantagonisten optreedt door vaatverwijding van de bloedvaten van de oogzenuw, blijkt geen belangrijk effect te zijn in de preventie van glaucoom. Tevens blijkt op basis van deze resultaten dat een vermindering van oculaire doorbloeding, die door antihypertensiva zou worden veroorzaakt, waarschijnlijk geen belangrijke factor van invloed op het ontstaan van glaucoom is. Dit is een interessant gegeven voor het inzicht in het pathofysiologische mechanisme van glaucoom. In 2006 rapporteerde een bevolkingsonderzoek uit Australie dat er mogelijk een relatie was tussen het gebruik van topicale beta-blokkers en cardiovasculaire sterfte. Daarmee werd er een oude discussie opnieuw aangezwengeld. Deze bevinding was merkwaardig, omdat beta-blokkers voor vele cardiovasculaire aandoeningen juist als therapeuticum geregistreerd zijn en vele gerandomiseerde studies op cardiologisch gebied de gunstige effecten van beta­blokkers op cardiovasculaire aandoeningen hebben aangetoond. In hoofdstuk 6 wordt het effect van het gebruik van topicale betablokkers op sterfte onder­zocht. Het resultaat van de groep uit Australie kon niet gereproduceerd worden. Veel meer 1 34 Chapter 8 
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Op 1 februari 2002 hen ik met mijn onderzoek in Groningen begonnen. In eerste instantie was het onderzoek gepland als een half jaar durend deelproject van de Groningen Longitudinale Glaucoom Studie. Dit mondde echter uit in een reeks van onderzoeken welke zich uitbreidde van Groningen naar Rotterdam en welke zich uitstrekte over mijn gehele opleidingsperiode tot oogarts en het jaar daarna. Het resultaat hiervan staat in dit proefschrift beschreven. Gedurende deze periode heh ik altijd met veel plezier samen­gewerkt met alle oogartsen, arts-assistenten, en alle andere medewerkers van de afdeling oogheelkunde in het UMCG en iedereen van de oogheelkundige afdeling van het ERGO bevolkingsonderzoek in Rotterdam. Hier maak ik graag gebruik van de gelegenheid om een aantal van deze mensen speciaal te bedanken voor hun steun, die instrumenteel was in het slagen van dit onderzoek. Pro£ dr. J.M.M. Hooymans, Anneke, mijn promotor, hen ik zeer dankbaar, daar ik van haar het vertrouwen kreeg om te werken op de afdeling oogheelkunde van het UMCG. Haar enthousiasme en steun hebben mijn opleiding tot oogarts en het voltooien van dit proefschrift mogelijk gemaakt. Dr. N.M. Jansonius, Nomdo, mijn co-promotor, is sinds het begin van mijn onderzoek een grote steun voor mij geweest. Zijn glasheldere denkwijze en vele ingenieuze ingevingen hebben een belangrijke bedrage geleverd aan de totstandkoming van dit proefschrift en aan mijn vorming als oogarts. Veel dank voor de kameraadschap en de altijd aanwezige steun en helpende hand. Prof. dr. P.T.V.M. de Jong, Paulus, mijn promotor, hen ik zeer erkentelijk, daar hij door zijn kritische instelling en grote kennis een onmiskenbare bijdrage heeft geleverd aan dit proefschrift. Pro£ dr. B.H.Ch. Stricker, Pro£ dr. U. Schiefer en Pro£ dr. R.P. Stolk, dank ik voor hun bereidwilligheid zitting te nemen in de beoordelingscommissie van dit proefschrift. Veel waardering en dank hen ik verschuldigd aan Govert Heeg, degene die mij op mijn eerste werkdag in Groningen heeft rondgeleid en mij vandaag op mijn promotie als para­nimf ter zijde staat. In de tussenliggende periode was hij altijd bereid mij gevraagd en onge­vraagd van advies re dienen. Hartelijk bedankt voor je aandacht, hulp en humor. De oogartsen en arts-assistenten van de afdeling oogheelkunde hebben mij door de jaren heen veel kennis en gezelligheid gegeven, bedankt hiervoor. Ella, Fenna, Stella en Albert wil ik hier bedanken voor hun goede ondersteuning. Dankwoord 139 
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